Aspirin assay

The invention describes a method for monitoring and detecting non-therapeutic, therapeutic and toxic concentrations of aspirin in individuals which uses the urinary salicylic acid to salicyluric acid ratio.

Detection of Synthetic Cannabinoids

The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits. 2. The immunogen of claim 1 , wherein{'sub': n', 'n', '2, 'for structures (a), (b), (c), (d) and (f), the crosslinker is —X—Y— in which Y is chosen from carbonyl, amino, thiol, maleimide, isocyanato, isothiocyanato, aldehyde, diazo and dithiopyridyl and is attached to the accm, and X for structure (a) is —(CO)-D- where n=0 or 1, and D which is attached to Y is a C1-10 substituted or unsubstituted straight chain alkylene or arylene moiety, and X for structures (b), (c), (d) and (f) is -(A)D- where A=O, —N(R)—, S, —S(O)— or —S(O)— in which R═H or C1-5 alkyl, n=0 or 1, D which is attached to Y is a C1-10 substituted or unsubstituted straight chain alkylene or arylene moiety;'}{'sub': 'p', 'for structure (e) m=1-3, the crosslinker is either -(L)-M-Q- or ═N—O-M-Q- in which Q, which is attached to the accm, is chosen from carbonyl, amino, thiol, maleimide, isocyanato, isothiocyanato, aldehyde, diazo and dithiopyridyl, M is a C1-10 substituted or unsubstituted straight chain alkylene or arylene moiety, p=0 or 1 and L is O, NH, S, ester, thioester, or amide;'}{'sub': 'p', 'for structure (g) m=1-3, the crosslinker is -(L)-M-N— in which N, which is attached to the accm, is either carbonyl or amino, M is a C1-10 substituted or unsubstituted straight chain alkylene or arylene moiety, p=0 or 1 and L is O, NH, S, ester, thioester, or amide.'}3. The immunogen of comprising structure (c) claim 2 , and wherein the crosslinker extends from the 5-position of the indole ring.4. The immunogen of claim 2 , comprising structure (a) claim 2 , wherein Y=carbonyl claim 2 , n=0 and D=pentylene.5. The immunogen of claim 2 , comprising structure (c) claim 2 , wherein the crosslinker extends from the 5-position of the indole ring claim 2 , Y=carbonyl claim 2 , A=O claim 2 , n=1 ...

IMMUNODETECTION AND QUANTIFICATION OF PYRAZOLOPYRIMIDINE SEDATIVES

The invention relates to novel immunogens, antibodies, methods and kits for use in immunoassays to detect and quantify zaleplon, metabolites of zaleplon and indiplon. These are the first described immunoassays for these compounds and have greater sensitivity than alternative analytical techniques. 117-. (canceled)19. The immunogen of wherein n=1 claim 18 , and the crosslinker is —X—Y—Z— claim 18 , wherein X is a heteroatom; Y is a C-C claim 18 , substituted or unsubstituted straight chain alkylene moiety claim 18 , or arylene moiety; and Z (before conjugation with the accm) is selected from a carboxy claim 18 , a dithiopyridyl claim 18 , a maleimide claim 18 , an amino claim 18 , a hydroxyl claim 18 , a thiol claim 18 , a thioester and an aldehyde moiety.20. The immunogen of wherein X is nitrogen claim 19 , Y is propylene and Z (before conjugation with the accm) is a carboxy group.21. An antibody raised against the immunogen of claim 18 , wherein the antibody binds to an epitope of zaleplon claim 18 , 5-oxozaleplon or indiplon.22. A method of detecting or determining an amount of one or more of zaleplon claim 21 , 5-oxozaleplon or indiplon in a solution or an in vitro sample taken from an individual claim 21 , the method comprising contacting the sample or the solution with a conjugate and an antibody of claim 21 , detecting the bound conjugate claim 21 , and deducing from calibration value(s) the presence of or the calibrator-equivalent amount of one or more of zaleplon claim 21 , 5-oxozaleplon or indiplon.23. A kit for detecting or determining one or more of zaleplon claim 21 , 5-oxozaleplon or indiplon claim 21 , the kit comprising an antibody of .24. The kit of further comprising at least one conjugate and/or at least one calibrator.26. The immunogen of wherein n=1 claim 25 , and the crosslinker is —X—Y—Z— claim 25 , wherein X is a heteroatom claim 25 , Y is a C-C claim 25 , substituted or unsubstituted straight chain alkylene moiety claim 25 , or arylene moiety ...

Glutathione S-Transferase Omega 1 Wild Type Specific Antibody

The invention relates to a novel antibody which binds to wild type (wt) Glutathione S-transferase Omega 1 (wtGSTO1) but not to mutant (mut) GSTO1 and methods and uses based on the antibody. The antibody is based on novel haptens and immunogens. 3. An immunogen comprising a polypeptide hapten of coupled to an immunogenicity conferring carrier molecule.4. An antibody raised from an immunogen of which specifically binds to wtGSTO1 and does not bind to mutGSTO1.5. The antibody of which is a monoclonal antibody.8. A kit for detecting and/or determining the presence of wtGSTO1 claim 4 , mut GSTO1 claim 4 , or a combination thereof claim 4 , in a sample claim 4 , comprising an antibody of . The present invention relates to the detection of wtGSTO1 and mutGSTO1 enzymes. Specifically, the invention describes novel immunogens, novel antibodies and methods for detecting wtGSTO1 and mutGSTO1 enzymes, and their use in disease research, diagnosis and treatment.Glutathione transferases (GSTs) are a multi-gene enzyme family which through catalyzing a number of distinct glutathione dependent reactions play critical roles in providing protection against electrophiles and products of oxidative stress. Multiple cytosolic and membrane-bound GST isoenzymes with divergent catalytic and non-catalytic binding properties are found in all eukaryotic species. The mammalian cytosolic GSTs are made up of Alpha (A), Mu (M), Omega (O), Pi (P), Sigma (S), Theta (T) and Zeta (Z) families (Strange et al., 2001). The most recently discovered class of cytosolic GSTs, the Omega class (GSTO1 and GSTO2), are characterised by a unique N-terminal extension and a cysteine residue in the active site, which is distinct from the tyrosine and serine residues associated with other GST classes. GSTO1 (Board et al., 2000) exhibits glutathione-dependent thiol transferase and dehydroascorbate reductase activites characteristic of glutaredoxins and which are not associated with other GSTs. The polypeptide consists of ...

SENSITIVE AND GENERIC ANTIBODIES AND MULTIPLE APPLICATIONS

The invention relates to the detection and quantification of carbamazepine drugs and their metabolites. The invention is underpinned by novel polyclonal antibodies with unique binding properties which enable immunoassay methods and kits for various applications. 5. The immunogen of claim 2 , wherein X is selected from a Cchain alkyl claim 2 , alkenyl claim 2 , and alkynyl group claim 2 , which can be branched or unbranched claim 2 , substituted or unsubstituted claim 2 , linear or cyclic.6. The immunogen of claim 2 , wherein X is selected from a Cchain alkyl claim 2 , alkenyl claim 2 , and alkynyl group claim 2 , which can be branched or unbranched claim 2 , substituted or unsubstituted claim 2 , linear or cyclic.7. The immunogen of claim 3 , wherein X is selected from a Cchain alkoxyl claim 3 , alkenoxyl claim 3 , and alkynoxyl group claim 3 , which can be branched or unbranched claim 3 , substituted or unsubstituted claim 3 , linear or cyclic.8. The immunogen of claim 3 , wherein X is selected from a Cchain alkoxyl claim 3 , alkenoxyl claim 3 , and alkynoxyl group claim 3 , which can be branched or unbranched claim 3 , substituted or unsubstituted claim 3 , linear or cyclic.9. The immunogen of claim 4 , wherein Y is selected from a Cchain alkyl claim 4 , alkenyl claim 4 , and alkynyl group claim 4 , which can be branched or unbranched claim 4 , substituted or unsubstituted claim 4 , linear or cyclic.10. The immunogen of claim 4 , wherein Y is selected from a Cchain alkyl claim 4 , alkenyl claim 4 , or alkynyl group claim 4 , which can be branched or unbranched claim 4 , substituted or unsubstituted claim 4 , linear or cyclic.11. The immunogen of claim 3 , wherein X is —O—CH— and Z is a carbonyl group.12. An antibody derivable from the immunogen of .13. The antibody of capable of binding to at least one epitope of an analyte selected from carbamazepine claim 12 , carbamazepine-10 claim 12 ,11-epoxide claim 12 , 10 claim 12 ,11-dihydro-10-hydroxycarbamazepine claim ...

Detection of Synthetic Cannabinoids

The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the CP family. Unique antibodies derived from novel immunogens enable said methods and kits. 2. The antibody of claim 1 , in which there are 2 hydrogen substituents at position 6 of the cyclohexyl ring.3. The antibody of claim 1 , in which there is a hydrogen substituent at position 5 of the phenyl ring.4. The antibody of in which there is a hydrogen substituent at position 6 of the phenyl ring.5. The antibody of which binds to an epitope selected from the group consisting of a racemic mixture of (±)-CP-47 claim 1 ,497 (Chomologue) claim 1 , a racemic mixture of (+)-CP-47 claim 1 ,497 (Chomologue) claim 1 , a stereoisomer of CP-47 claim 1 ,497 (Chomologue) and a stereoisomer of CP-47 claim 1 ,497 (Chomologue).6. The antibody of further characterised by having a B/Bof ≦50% for the epitope in which there is a hydrogen substituent at position 6 of the phenyl ring (standardised with (±)-CP-47 claim 1 ,497 (Chomologue) and using a tracer (C).7. The antibody of further characterised by having a B/Bof ≦50% for an epitope selected from the group consisting of a racemic mixture of (±)-CP-47 claim 6 ,497 (Chomologue) and a racemic mixture of (±)-CP-47 claim 6 ,497 (Chomologue) (standardised with (±)-CP-47 claim 6 ,497 (Chomologue) and using a tracer (C).9. The antibody of raisable against the immunogen of structure (e) and having a B/Bof ≦50% (standardised with (+)-CP-47 claim 8 ,497 (Chomologue) and using a tracer (C).10. The antibody of in which m=1-3 claim 9 , the crosslinker is either -(L)-M-Q- or ═N—O-M-Q- in which Q claim 9 , which is attached to the accm claim 9 , is chosen from carbonyl claim 9 , amino claim 9 , thiol claim 9 , maleimide claim 9 , isocyanato claim 9 , isothiocyanato claim 9 , aldehyde claim 9 , diazo and dithiopyridyl claim 9 , M is a Csubstituted or unsubstituted straight chain alkylene or arylene moiety claim 9 , p=0 or 1 and L is O ...

Detection of Synthetic Cannabinoids

The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits. 3. The antibody of which binds to an epitope of the molecules JWH-015 and JWH-016.4. The antibody of further characterised by being raisable from an immunogen of structure VII.5. The antibody of further characterised by having a B/Bof ≦20% in Table 4 (standardised with RCS-4 and using tracer ESC6585).7. The antibody of in which Ris selected from H; substituted methyl claim 6 , substituted ethyl claim 6 , substituted or unsubstituted propyl claim 6 , substituted or unsubstituted butyl claim 6 , substituted or unsubstituted pentyl or hexyl.8. The antibody of in which R claim 6 , if present claim 6 , is present at one of positions 5 claim 6 , 6 or 7 of the indole ring.9. The antibody of in which claim 6 , when X is substituted naphthyl claim 6 , the naphthyl is substituted at the 6 position of the naphthyl ring or claim 6 , when X is substituted phenyl claim 6 , the phenyl is substituted at position 2 of the phenyl ring.10. The antibody of further characterised by being raisable from an immunogen of structure I.11. The antibody of further characterised by having a B/Bof ≦16% in Table 4 (standardised with JWH-018 and using tracer ESC6557).13. The antibody of in which Ris selected from butyl claim 12 , pentyl claim 12 , substituted pentyl selected from 4-fluoropentyl and 5-fluoropentyl claim 12 , 4-pentenyl and hexyl.14. The antibody of further characterised by having been derived from an immunogen of structure II.15. The antibody of further characterised by having a B/Bof ≦15% in Table 4 (standardised with JWH-018 and using tracer ESC6557).17. The antibody of in which Ris selected from butyl claim 16 , substituted butyl selected from 3-methylbutyl; pentyl; substituted pentyl selected from 4-fluoropentyl and 5-fluoropentyl; and 4-pentenyl.18. The ...

Reagent bottles, valves therefor, washing modules and methods and apparatus for dispensing reagents

A valve for a reagent bottle is provided, the valve including a resilient membrane configured to extend across an opening in the reagent bottle, the resilient membrane having at least one slit extending therethrough. Also disclosed is a dispensing apparatus for dispensing a reagent from a reagent bottle, the dispensing apparatus comprising: a probe assembly having a probe adapted for insertion into the reagent bottle through the valve and an extraction mechanism for drawing reagent out of the reagent bottle through the probe. A valve opening assembly is provided, which is adapted to open the valve of the reagent bottle such that the probe can pass through the valve without contacting the valve.

Detection of Synthetic Cannabinoids

The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and RCS families. Unique antibodies derived from novel immunogens enable said methods and kits.

IMMUNOASSAY FOR PYRROLIDINOPHENONES

The invention describes antibodies that bind molecules of the pyrrolidinophenone class of synthetic drugs. The antibodies are derived from novel chemical intermediates, haptens and immunogens and are used in methods and kits to detect and quantify pyrrolidinophenones. 2. The hapten or immunogen of in which for the hapten X is O claim 1 , Y is —C(O)—CH—CH— claim 1 , Z is carboxy or amino and Q is ethyl or propyl; and for the immunogen X is O claim 1 , Y is —C(O)—CD— claim 1 , Z is carboxy or amino claim 1 , Q is ethyl or propyl and the accm is BTG claim 1 , BSA or KLH.4. The antibody of which is able to bind to at least one structural epitope of any of the molecules (RS)-1-(benzo[d][1 claim 3 ,3]dioxol-5-yl)-2-(pyrrolidin-1-yl)butanone claim 3 , (RS)-1-(2-naphthyl)-2-(pyrrolidin-1-yl)pentanone claim 3 , (RS)-1-(4-methylphenyl)-2-(pyrrolidin-1-yl)butanone claim 3 , (RS)-1-(benzo[d][1 claim 3 ,3]dioxol-5-yl)-2-(pyrrolidin-1-yl)pentanone or (RS)-1-(benzo[d][1 claim 3 ,3]dioxol-5-yl)-2-(pyrrolidin-1-yl)propanone.5. A method of detecting or determining one or more pyrrolidinophenones in an in vitro sample or in a solution the method comprising contacting the sample or solution with at least one detecting agent and at least one antibody of ; detecting or determining the detecting agent(s); and deducing from a calibration curve the presence of claim 3 , or amount of claim 3 , pyrrolidinophenones in the sample or solution.6. The method of in which the pyrrolidinophenones to be detected or determined are one or more of (RS)-1-(benzo[d][1 claim 5 ,3]dioxol-5-yl)-2-(pyrrolidin-1-yl)butanone claim 5 , (RS)-1-(2-naphthyl)-2-(pyrrolidin-1-yl)pentanone claim 5 , (RS)-1-(4-methylphenyl)-2-(pyrrolidin-1-yl)butanone claim 5 , (RS)-1-(benzo[d][1 claim 5 ,3]dioxol-5-yl)-2-(pyrrolidin-1-yl)pentanone and (RS)-1-(benzo[d][1 claim 5 ,3]dioxol-5-yl)-2-(pyrrolidin-1-yl)propanone.8. The compound of in which X is OH and Q is ethyl or propyl.9. A kit for detecting or determining ...

BIOCHIP WELL, SEALED WELL ASSEMBLY, CARTRIDGE THEREFOR, AND APPARATUS AND METHODS FOR OPENING SEALED WELLS

A biochip well is disclosed, including a vessel containing a well therewithin, the vessel forming at least base and side walls of the well and defining at least one aperture giving access to the well, and further including retaining means for holding a biochip at a predetermined position within the well, the well including a laterally offset region into which the biochip does not protrude when held at the predetermined position by the retaining means. Also disclosed are sealed well assemblies and apparatus and methods for opening sealed wells. 166-. (canceled)67. An apparatus for opening a sealed well in a vessel , wherein the well is sealed by a sealing sheet affixed to the vessel , the apparatus comprising:a guide structure configured to receive the vessel and to constrain movement of the vessel along a vessel path;the guide structure being further configured to receive the sealing sheet and to define a sealing sheet path along which the sealing sheet can be driven; anda drive mechanism adapted to drive the sealing sheet along the sealing sheet path and/or to drive the vessel along the vessel path;wherein a first section of the vessel path and of the sealing sheet path are parallel and, at a position downstream of the first section, the vessel path and the sealing sheet path diverge such that, in the first section, when the sheet and/or vessel is driven, the vessel and sheet remain affixed to one another and, at the diverging position, the sheet is stripped off the vessel, thereby opening the well.68. An apparatus according to wherein the guide structure is provided claim 67 , at least in part claim 67 , in the form of a cartridge which is removable from and reinsertable into the apparatus.69. An apparatus according to wherein the guide structure comprises a vessel guide and a sealing sheet guide.70. An apparatus according to comprising a plurality of guide structures as defined in .71. An apparatus according to wherein the plurality of guide structures are ...

Assay for the Detection of the Phenylpiperazine Family

The current invention describes novel immunogens which are used in the production of novel antibodies with unique binding properties in that they cross-react with a variety of phenylpiperazine derivatives. These antibodies enable methods and kits to detect and/or determine phenylpiperazine derivatives (for example mCPP, TFMPP and MeOPP) in an in vitro sample which are advantageous over currently available analytical methods in terms of cost, ease of use, speed and sensitivity. 2. An immunogen comprising a hapten of conjugated to an antigenicity-conferring carrier material.3. The immunogen of in which D of -(A)-B-D is coupled to the antigenicity-conferring carrier material.4. The immunogen of which is either 1-(3-carboxyphenyl)piperazine or 1-(4-carboxymethyletherphenyl)piperazine is coupled to the antigenicity-conferring carrier material.5. The immunogen of in which the antigenicity-conferring carrier material is selected from BTG claim 2 , BSA claim 2 , and KLH.6. An antibody raised against the immunogen of .7. An antibody raised against the 1-(3-carboxyphenyl)piperazine immunogen of having specificity for 1-(3-methylphenyl)piperazine with an ICvalue of around 1 ng/ml claim 4 , which is further characterised by having cross-reactivity to 1-(3-chlorophenyl)piperazine claim 4 , 1-phenylpiperazine claim 4 , 1-(4-methoxyphenyl)piperazine claim 4 , 1-(4-hydroxyphenyl)piperazine claim 4 , 1-(4-fluorophenyl)piperazine claim 4 , 1-(3-hydroxyphenyl)piperazine claim 4 , 1-(3-trifluoromethylphenyl)piperazine and 1-(2-methoxyphenyl)piperazine.8. An antibody raised against the 1-(4-carboxymethyletherphenyl)piperazine immunogen of having specificity for 1-(3-methylphenyl)piperazine with an ICvalue of around 1 ng/ml claim 4 , which is further characterised by having cross-reactivity to 1-(3-chlorophenyl)piperazine claim 4 , 1-phenylpiperazine claim 4 , 1-(4-methoxyphenyl)piperazine claim 4 , 1-(4-hydroxyphenyl)piperazine claim 4 , 1-(4-fluorophenylpiperazine claim 4 , 1-(3- ...

MULTI-ANALYTE MICROARRAYS USING TAG-SPECIFIC ANTIBODIES AND TAG-ANCHORED ANTIBODIES

The invention describes accurate and flexible methods and kits for conducting multi-analyte microarrays through the use of Tag-specific antibodies and analyte-specific Tag-anchored antibodies. 1. A method for detecting or determining two or more analytes in a sample comprising adding the sample , two or more analyte-specific Tag-anchored antibodies and two or more labeled conjugates to a solid support comprising two or more Tag-specific antibodies at spatially-defined locations on the solid support , each Tag-specific antibody recognizing a different Tag; and detecting or determining the amount of two or more analytes in the sample by detecting and measuring the signal from the labeled conjugates and comparing the measured values with values from calibrators , characterized in that the two or more analyte specific Tag-anchored antibodies comprise at least one analyte-specific Tag anchored antibody which is specific for an analyte that is a macromolecule and at least one analyte-specific Tag-anchored antibody which is specific for an analyte that is a small molecule.2. (canceled)3. The method of in which the Tags of the analyte-specific Tag-anchored antibodies are small molecules having a molecular weight of less than approximately 5 claim 1 ,000 Daltons.4. The method of in which the labeled conjugates are labeled antibodies for sandwich assays and labeled haptens for competitive assays.5. A kit for detecting or determining two or more analytes in a sample comprising two or more Tag-specific antibodies at spatially-defined locations on a solid support and two or more tag-conjugated analyte-specific antibodies claim 1 , characterized in that the two or more analyte specific Tag-anchored antibodies comprise at least one analyte-specific Tag anchored antibody which is specific for an analyte that is a macromolecule and at least one analyte-specific Tag-anchored antibody which is specific for a small molecule.6. The kit of in which the solid support also supports analyte ...

Assay for Benzylpiperazine and Metabolites

The invention relates to the detection and quantification of 1-benzylpiperazine and its metabolites. The invention is underpinned by novel polyclonal antibodies with unique binding properties which enable immunoassay methods and kits for various applications. 3. The immunogen of claim 1 , wherein the accm (antigenicity conferring carrier material) is selected from bovine serum albumin (BSA) claim 1 , egg ovalbumin claim 1 , bovine gamma globulin claim 1 , bovine thyroglobulin (BTG) claim 1 , keyhole limpet haemocyanin (KLH) claim 1 , synthetic poly(amino acids) having a sufficient number of available amino groups claim 1 , lysine claim 1 , and synthetic or natural polymeric materials bearing reactive functional groups.5. The immunogen of claim 4 , wherein the immunogen has the general structure (I); accm is bovine serum albumin (BSA); and the cross-linker has the general structure (II) claim 4 , wherein n=1; X is present and is attached to the aromatic ring moiety of the immunogen and is O; Y is a Cunsubstituted alkylene moiety; and Z (before conjugation with the accm) is a carboxyl moiety.6. The immunogen of claim 4 , wherein the immunogen has the general structure (I) claim 4 , wherein accm is bovine thyroglobulin (BTG); and the cross-linker has the general structure (II) claim 4 , wherein n=1; X is present and is attached to the aromatic ring moiety of the immunogen and is O; Y is a Cunsubstituted alkylene moiety; and Z (before conjugation with the accm) is a carboxyl moiety.8. The immunogen of claim 7 , wherein the immunogen has the general structure (I); accm is bovine serum albumin (BSA); and the cross-linker has the general structure (II) claim 7 , wherein n=O; Y is attached to the piperazine moiety of the immunogen and is a Cunsubstituted alkylene moiety; and Z (before conjugation with the accm) is a carboxyl moiety.9. The immunogen of claim 7 , wherein the immunogen has the general structure (I) claim 7 , accm is bovine thyroglobulin (BTG); and the cross- ...

IMMUNOASSAYS FOR MEPERIDINE AND METABOLITES

The invention provides novel haptens and immunogens for the preparation of novel monoclonal antibodies, which detect the synthetic opioid meperidine and its active metabolite normeperidine. These antibodies enable methods and kits, which are useful in an immunoassay for therapeutic drug monitoring (TDM) and in extending the window of detection for cases of abuse and drug-facilitated sexual assault (DFSA). 3. The immunogen of claim 2 , in which n=0 claim 2 , Y=ethylene and Z=carboxy.4. An antibody that can bind to an epitope of meperidine and normeperidine claim 1 , wherein the antibody is raised against the immunogen of .5. The antibody of claim 4 , further characterised by having a cross-reactivity of 100% to meperidine and a cross-reactivity of at least 50% to normeperidine.6. The antibody of claim 4 , wherein the antibody has a cross-reactivity to normeperidine of 80-120%.7. The antibody of claim 4 , wherein the antibody is monoclonal.8. Hybridoma cell line NM4.3F5.C10.B7.B2.B2.C4 claim 4 , deposited with the European Collection of Cell Cultures (ECACC) under deposit reference no. 12090501.9. An antibody produced by the hybridoma cell line of .10. An isolated monoclonal antibody or fragment thereof that binds an epitope to which a monoclonal antibody produced by the hybridoma of binds.11. A method of detecting or determining one or more of meperidine and normeperidine in an in vitro sample of an individual claim 4 , said method comprising: contacting the sample with one or more detecting agents and one or more antibodies according to ; detecting claim 4 , or determining the quantity of claim 4 , the one or more detecting agents; and deducing from calibrators claim 4 , the presence of or amount of one or more of meperidine and normeperidine in the sample.12. The antibody of claim 5 , wherein the antibody has a cross-reactivity to normeperidine of 80-120%.13. The antibody of claim 5 , wherein the antibody is monoclonal.14. The antibody of claim 6 , wherein the ...

ASSAY FOR METHOXETAMINE

Components for enabling immunodetection of methoxetamine are described including immunogens, haptens, antibodies and kits. 2. The immunogen of wherein:X is —NH—;{'sub': 2', 'n′, 'crosslinker is —(CH)—C(O)—; and'}n′ is 1-5.3. The immunogen of wherein:n′ is 5.4. An antibody raisable against the immunogen of .5. The antibody of which has <5% competitive cross-reactivity to any one of ketamine claim 4 , norketamine claim 4 , tramadol and tilidine compared with a 100% competitive cross-reactivity to methoxetamine.6. The antibody of which has an ICof <10 ng/ml for methoxetamine.7. The antibody of wherein the tracer is N-(5-carboxypentyl)-N-desethylmethoxetamine-HRP.8. The antibody of claim 4 , which has been purified.11. The antibody of which has <5% competitive cross-reactivity to any one of ketamine claim 9 , norketamine claim 9 , tramadol and tilidine compared with a 100% competitive cross-reactivity to methoxetamine.12. The antibody of wherein the tracer is N-(5-carboxypentyl)-N-desethylmethoxetamine-HRP.13. The antibody of claim 9 , which has been purified.14. A method of detecting or determining methoxetamine in a sample comprising:{'claim-ref': {'@idref': 'CLM-00004', 'claim 4'}, 'i) acting the sample with a detecting agent and an antibody of ; and'}ii) detecting or determining the amount of detecting agent bound to the antibody.16. The method of claim 15 , wherein the detectable label is horseradish peroxidase (HRP).17. The method of claim 16 , wherein the presence of the detectable label is detected or determined by a colour change in response to reaction of the labelling agent with a substrate.18. The method of claim 17 , wherein the colour change is detected or determined by reading the absorbance at 450 nm.19. A kit comprising an antibody of and optionally a detecting agent. The instant application claims the benefit of priority under 35 USC §119 to United Kingdom Application No. 1511725.2, entitled “Assay” filed 3 Jul. 2015, the entire contents of which are ...

Determination of glycosylation signature

The present invention also describes use of a patient protein glycosylation profile to identify the presence or absence of a disease in subjects.

CHEMILUMINESCENCE DETECTOR

The present invention provides a chemiluminescence detector, which comprises an image capture device sensitive to chemiluminescence located within a container. The container has an array of apertures located in a field of view of the image capture device, and each aperture is defined by a through-bore in a wall of the container. The exterior of the container is engagable with a plurality of sample holders, each sample holder being in alignment with a respective aperture when engaged with the exterior of the container. The passage of light into the container through each aperture is restrictable by a closure device, passage of light into the container through the apertures is thereby controllable. 1. A chemiluminescence detector , comprising:an image capture device sensitive to chemiluminescence located within a container, the container having an array of apertures located in a field of view of the image capture device, each aperture being defined by a through-bore in a wall of the container, the exterior of the container being engagable with a plurality of sample holders, each sample holder being in alignment with a respective aperture when engaged with the exterior of the container, wherein passage of light into the container through each aperture is restrictable by a closure device, passage of light into the container through the apertures thereby being controllable.2. The detector according to claim 1 , wherein a plurality of walls define the container claim 1 , at least a part of the plurality of walls being separable from the container.3. The detector according to claim 2 , wherein each separable part of the plurality of walls has a perimeter surface abutable to a complementary perimeter surface of the plurality of walls claim 2 , said perimeter surfaces forming a complementary pair of perimeter surfaces claim 2 , each respective complimentary pair of perimeter surfaces being configured to suppress light ingress to the interior of the container.4. The detector ...

Diagnosis of cancer by detecting dimeric il-18

The present invention describes methods for screening for cancer in a subject, by measuring the level of dimeric IL-18 in a sample obtained from the subject, and comparing that level with the level in a normal control sample. The present invention also describes an assay for screening for cancer in a subject, by measuring the level of dimeric IL-18 in a sample obtained from the subject, whereby an elevated level of dimeric IL-18 is indicative of cancer.

BIOLOGICAL STATUS CLASSIFICATION

There is provided a method of classifying a biological status of an individual. The method comprising: obtaining a biological sample from a patient; obtaining health-related information from the patient, said information including patient gender; analysing the sample to identify a quantity of each of 2 or more endogenous analytes in the sample; comparing the analyte quantities to reference data from healthy individuals to classify the patient as healthy, pre-diseased, at risk of disease or diseased for at least one health-related condition. The reference data includes data derived from a group of biological samples of individuals having the same gender as the patient and not having a need for medical treatment for a disease or illness, each biological sample of the group of biological samples having been analysed by the same process as used to analyse the patient sample, the process being monitored to maintain a predetermined level of consistency. 1. In a method of treating an individual in which a biological sample of the individual is analysed to identify a quantity of each of 2 or more endogenous analytes in the sample and the analyte quantities are compared to reference data to classify the individual as healthy , pre-diseased , at risk of disease or diseased for at least one health-related condition , and upon finding the individual is pre-diseased , at risk of disease , or diseased , applying an appropriate medical treatment to the individual , the improvement comprising:using reference data derived from a group of biological samples of individuals having the same gender as the individual and not having a need for medical treatment for a disease or illness, each biological sample of the group of biological samples having been analysed by the same process as used to analyse the individual sample.2. The method according to claim 1 , wherein each biological sample of the group of biological samples is a biological sample obtained from individuals at a single site ...

Immunoassay for Phenethylamines of the 2C and DO Sub-Families

Immunoassay methods and their requisite components for the detection and determination of phenethylamines of the 2C and DO sub-families are described. 1. An immunoassay method of detecting phenethylamines of an antibody specific to phenethylamines of the 2C sub-family that does not cross-react with phenethylamines of the DO sub-family and an antibody specific to phenethylamines of the DO sub-family that does not cross-react with phenethylamines of the 2C sub-family for i);', 'or an antibody specific to phenethylamines of the 2C sub-family that does not cross-react with phenethylamines of the DO sub-family for ii);', 'or an antibody specific to phenethylamines of the DO sub-family that does not cross-react with phenethylamines of the 2C sub-family for iii); and', 'measuring a signal or signals produced by the one or more detecting agents; and, 'i) 2C and DO sub-families, ii) 2C sub-family or iii) DO sub-family, the method comprising contacting a sample, wherein the sample is suspected of containing phenethylamines, with one or more detecting agents anddeducing from a calibration curve the presence of, or amount of, phenethylamines of the sub-family 2C, the sub-family DO or both the 2C and DO sub-families.2. The immunoassay method of in which the antibody specific to phenethylamines of the 2C sub-family is derived from an immunogen derivatised through the 4-position of 2 claim 1 ,5-dimethoxyphenethylamine and the antibody specific to phenethylamines of the DO sub-family is derived from an immunogen derivatised through the 4-position of 2 claim 1 ,5-dimethoxy-N-methylphenethylamine.4. The method of in which Ris H.5. The method of in which n1 and n2=1 claim 4 , A is —N(H)— claim 4 , alk is a terminally substituted alkylene claim 4 , optionally —S—CH—CH—C(O)—; Y is 4-(succinimido-N-methyl)cyclohexylcarbonyl; and Z is BSA.7. The antibody of in which Structure II is selected from 2C-B claim 6 , 2C-P claim 6 , 2C-E claim 6 , 2C-T-2 claim 6 , 2C-C claim 6 , 2C-T-7 claim 6 , ...

METHOD OF EXTRACTING MATERIAL FROM A FLUID AND EXTRACTOR

There is provided a method of extracting material from a fluid method of extracting material from a fluid, the fluid being held within a fluid chamber. The method comprises drawing, with a magnetic field generating system, at least one magnetically susceptible member through the fluid around a closed path between at least three points in the chamber, said at least one member being adapted to bind to material in fluid in the chamber. The at least three points are arranged relative to each other in a shape having at least two dimensions, the magnetic field generating system being configured to move the at least on magnetically susceptible member directly between the at least three points, material in the fluid binding to the at least one magnetically susceptible member when it comes into contact with the at least one member as it moves through the fluid. 1. A method of extracting material from a fluid , the fluid being held within a fluid chamber , the method comprising:drawing, with a magnetic field generating system, at least one magnetically susceptible member through the fluid around a closed path between at least three points in the chamber, said at least one member being adapted to bind to material in fluid in the chamber, whereinthe at least three points are arranged relative to each other in a shape having at least two dimensions, the magnetic field generating system being configured to move the at least one magnetically susceptible member directly between the at least three points, material in the fluid binding to the at least one magnetically susceptible member when it comes into contact with the at least one member as it moves through the fluid.2. The method according to claim 1 , wherein the magnetic field generating system is configured to draw the at least one magnetically susceptible member to two of the at least three points using a magnetic field and to allow the at least one magnetically susceptible member to travel to the third point of the at least ...

Venlafaxine Assay

The invention describes antibodies that bind venlafaxine and O-desmethylvenlafaxine. The antibodies are derived from novel haptens and immunogens and are used in methods and kits to detect and quantify venlafaxine and O-desmethylvenlafaxine. The invention also describes novel detecting agents which can be used in the methods and kits of the invention. 2. The hapten of claim 1 , wherein the hapten has the general formula IA; wherein R is attached at the para position of the phenyl moiety; and has the general structure —(X)n-Y—Z; wherein X is O; n=1; Y is an unsubstituted C1 straight chain alkylene moiety; and Z is a carboxyl moiety.3. The hapten of claim 1 , wherein the hapten has the general formula IA; wherein R is attached at the para position of the phenyl moiety; and has the general structure —(X)n-Y—Z; wherein X is O; n=1; Y is an unsubstituted C1 straight chain alkylene moiety; and Z is an aldehyde moiety claim 1 , optionally a homocysteine thiolactone aldehyde moiety.5. The detecting agent of claim 4 , wherein Z has the general structure -A-B claim 4 , in whichA is selected from the group consisting of a carboxyl, dithiopyridyl, maleimidyl, amino, hydroxyl, thiol, and aldehyde moiety; andB is a detecting label selected from the group consisting of an enzyme, luminescent substance, and a radioactive label.6. The detecting agent of claim 4 , wherein the detecting agent has the general formula IC; wherein R is attached at the para position of the phenyl moiety; and has the general structure —(X)n-Y—Z; wherein X is O; n=1; Y is an unsubstituted C1 straight chain alkylene moiety; and Z is a carboxyl moiety; and further comprises a detecting label enzyme claim 4 , optionally horseradish peroxidase (HRP).10. A method of detecting or determining venlafaxine and O-desmethylvenlafaxine in an in vitro sample or in a solution; the method comprising contacting the sample or solution with at least one antibody capable of binding claim 4 , optionally selectively binding ...

DETECTION OF INDAZOLE SYNTHETIC CANNABINOIDS

Components for enabling immunodection of indazole synthetic cannabinoids are described including immunogens, haptens, antibodies, methods and kits. 2. The immunogen of claim 1 , wherein:{'sub': 'n', 'Y is -(A)-B-D-;'}A is a functional group or heteroatom enabling attachment of the crosslinking group to the indazole;{'sub': '1-10', 'B is a Csubstituted or unsubstituted alkylene moiety optionally incorporating an aryl, cycloalkyl and/or a heterocyclic moiety;'}D is a functional group or heteroatom enabling attachment of the crosslinking group to the antigenicity-conferring carrier material; andn=0 or 1.3. The immunogen of claim 2 , wherein:n=0; and{'sub': 2', '2', '2', '2, 'D is —C(O)—, —NH—, —C═, —C(O)—NH—, —S—, —C(O)—NH—, —C(O)—NH—CH(COOH)—CH—CH—S—, or —C(O)—NH—CH(COOH)—CH—CH—S-maleimide-.'}47.-. (canceled)10. The antibody of claim 8 , which has a cross-reactivity of 100% to AB-Pinaca Pentanoic acid and greater than 50% cross-reactivity to AB-Pinaca claim 8 , 1-(5-hydroxypentyl) AB-Pinaca claim 8 , 1-(4-hydroxypentyl) AB-Pinaca claim 8 , and 5-fluoropentyl AB-Pinaca.11. The antibody of claim 8 , which has a cross-reactivity of 100% to AB-Pinaca Pentanoic acid and greater than 75% cross-reactivity to 1-(5-hydroxypentyl) AB-Pinaca claim 8 , 1-(4-hydroxypentyl) AB-Pinaca claim 8 , and 5-fluoropentyl AB-Pinaca.12. The antibody of claim 8 , which has a cross-reactivity of 100% to AB-Pinaca Pentanoic acid and greater than 50% cross-reactivity to AB-Pinaca claim 8 , 1-(5-hydroxypentyl) AB-Pinaca claim 8 , 1-(4-hydroxypentyl) AB-Pinaca claim 8 , and 5-fluoropentyl AB-Pinaca and less than 50% to AB-Fubinaca.13. The antibody of claim 8 , which has an ICof less than about 20 ng/ml to AB-Pinaca claim 8 , 1-(5-hydroxypentyl) AB-Pinaca claim 8 , 5-fluoropentyl AB-Pinaca claim 8 , AB-Pinaca Pentanoic acid claim 8 , and AB-Fubinaca.1418.-. (canceled)20. The method of claim 19 , in which the compound of structure IIIb is one or more of AB-Pinaca claim 19 , 1-(5-hydroxypentyl) AB- ...

METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE

The present invention relates to methods for the diagnosis of subjects that have or are at risk of having Alzheimer's disease (AD). In particular the present invention identifies individuals who have or are at risk of having AD through measurement of the levels of Afamin in combination with at least one other biomarker such as Alpha-1-antichymotrypsin, Alpha-2-macroglobulin, ApoB100, Complement C5, Serine threonine protein kinase TBK1 or Complement C3 in a fluid sample taken from a subject. Furthermore, genotype (Apolipoprotein E or glutathione S-transferase Omega) may also be taken into consideration and used within classification algorithms to determine the probability of a subject having or being at risk of having AD. 1. A method of diagnosing or monitoring a person at risk of developing or having Alzheimer's disease (AD) comprising obtaining a fluid sample from a person suspected of having or at risk of developing AD , measuring the concentration or relative level of the biomarker Afamin and at least one additional biomarker selected from Alpha-1 antichymotrypsin , Alpha-2-macroglobulin , Apolipoprotein B100 , complement C3 , Serine threonine kinase TBK-1 , vitamin D binding protein , alpha-1-B glycoprotein , hemopexin , serum albumin , ceruloplasmin , alpha-2-antiplasmin , apolipoprotein A1 , complement factor H , IgG , IgG Fc binding protein , hornerin , fibrinogen , complement C5 in the fluid sample , and establishing the significance of the concentrations or relative levels.2. The method according to claim 1 , wherein the measured concentration or relative level of Afamin and at least one of Alpha-1 antichymotrypsin Alpha-2-macroglobulin claim 1 , Serine threonine protein kinase TBK1 claim 1 , Apolipoprotein B100 claim 1 , Complement C3 claim 1 , vitamin D binding protein claim 1 , alpha-1-B glycoprotein claim 1 , hemopexin claim 1 , serum albumin claim 1 , ceruloplasmin claim 1 , alpha-2-antiplasmin claim 1 , apolipoprotein A1 claim 1 , complement factor H ...

Immunoassay for pyrrolidinophenones

The current invention provides an improved immunoassay for the detection and determination of pyrrolidinophenone based designer drugs in hair and biological fluids (urine, blood, and oral fluid). The generic immunoassay is underpinned by novel, sub-family-specific antibodies, which display surprising sensitivity. The invention further describes substrates comprising an antibody that is specific to compounds of the pyrrolidinophenone family. Also described are the novel immunogens from which the antibodies are derived and kits incorporating the antibodies of the current invention.

Detection of polymyxins

The present invention relates to antibodies for use in detecting polymyxins and tracers; and to a single-capture immunodetection method and kits, each utilising the antibodies of the invention, and disclosed tracers.

BIOCHIP WELL, SEALED WELL ASSEMBLY, CARTRIDGE THEREFOR, AND APPARATUS AND METHODS FOR OPENING SEALED WELLS

A biochip well is disclosed, including a vessel containing a well therewithin, the vessel forming at least base and side walls of the well and defining at least one aperture giving access to the well, and further including retaining means for holding a biochip at a predetermined position within the well, the well including a laterally offset region into which the biochip does not protrude when held at the predetermined position by the retaining means. Also disclosed are sealed well assemblies and apparatus and methods for opening sealed wells. 1. A biochip well comprising:a well within a vessel that forms at least base and side walls of the well and defines at least one aperture giving access to the well; anda retaining structure configured to hold a biochip at a predetermined position within the well,wherein the well includes a laterally offset region into which the biochip does not protrude when held at the predetermined position by the retaining structure.2. The biochip well according to claim 1 , wherein the laterally offset region is offset in the plane defined by the surface of the biochip when held at the predetermined position by the retaining structure claim 1 , and/or the shape and/or size of the laterally offset region is such that the biochip cannot be accommodated therewithin claim 1 , and/or the laterally offset region has a width which decreases with increasing distance from the predetermined position in which the biochip is held claim 1 , and/or the laterally offset region has a cross section in the lateral plane which is triangular claim 1 , curved claim 1 , semi-circular or semi-elliptical claim 1 , and/or wherein the retaining structure comprises one or more interference fit features provided on the side and/or base walls of the well claim 1 , adapted to grip the biochip in use claim 1 , and/or the retaining structure comprises at least one protrusion extending from an internal wall of the well claim 1 , the at least one protrusion being ...

DETECTION OF SYNTHETIC CANNABINOIDS

The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits. 15-. (canceled)7. The antibody of claim 6 , wherein the at least one molecule of the JWH family claim 6 , a metabolite thereof or a combination thereof is selected from JWH-018 claim 6 , JWH-073 claim 6 , JWH-200 claim 6 , JWH-398 claim 6 , JWH-081 claim 6 , JWH-018 N-pentanoic acid metabolite (M1) claim 6 , JWH-018 5-hydroxyindole metabolite (M2) claim 6 , JWH-018 4-hydroxyindole metabolite (M3) claim 6 , JWH-018 N-(5-hydroxypentyl) metabolite (M4) claim 6 , JWH-018 6-hydroxyindole metabolite (M5) claim 6 , JWH-018 N-(4-hydroxypentyl) metabolite claim 6 , 1-(5-fluoropentyl)indol-3-yl(1-naphthyl) methanone claim 6 , JWH-250 claim 6 , JWH-073 N-(3-hydroxybutyl) metabolite and JWH-073 N-(4-hydroxybutyl) metabolite.8. (canceled)9. (canceled)10. (canceled)11. The antibody of claim 6 , the antibody being able to bind to an epitope of JWH-073 claim 6 , JWH-200 claim 6 , JWH-398 claim 6 , JWH-018 claim 6 , JWH-018 N-pentanoic acid metabolite (M1) claim 6 , JWH-018 5-hydroxyindole metabolite (M2) claim 6 , JWH-018 4-hydroxyindole metabolite (M3) claim 6 , JWH-018 N-(5-hydroxypentyl) metabolite (M4) and JWH-018 6-hydroxyindole metabolite (M5).12. (canceled)13. The antibody of claim 6 , the antibody being specific to JWH-018 6-hydroxyindole metabolite (M5) and being cross-reactive to JWH-073 claim 6 , JWH-200 claim 6 , JWH-398 claim 6 , JWH-018 claim 6 , JWH-018 N-pentanoic acid metabolite (M1) claim 6 , JWH-018 5-hydroxyindole metabolite (M2) claim 6 , JWH-018 4-hydroxyindole metabolite (M3) and JWH-018 N-(5-hydroxypentyl) metabolite (M4).15. (canceled)16. (canceled)17. The method of claim 6 , wherein the synthetic cannabinoids to be detected or determined are selected from the group consisting of JWH-018 claim 6 , JWH-073 claim 6 , JWH-200 and JWH-398 and ...

LIQUID SAMPLE COLLECTION DEVICE

A liquid sample collection device is provided. The liquid sample collection device comprises a housing including a liquid collection chamber, and a liquid supply conduit extending from an inlet port and in use generally downwardly to the collection chamber, wherein the collection chamber includes an air vent port located such that in use liquid supplied to the collection chamber through the liquid supply conduit displaces air through the air vent port, and wherein the liquid supply conduit follows a meandering path including at least one air trap section defined at the junction between portions of the conduit extending with upward and downward components respectively, whereby in use once the air vent port is closed, air is displaced along the liquid supply conduit until it is trapped by the air trap section thereby preventing further liquid flow through the conduit. 1. A liquid sample collection device comprising:a housing including a liquid collection chamber, and a liquid supply conduit extending from an inlet port and in use generally downwardly to the collection chamber, wherein the collection chamber includes an air vent port located such that in use liquid supplied to the collection chamber through the liquid supply conduit displaces air through the air vent port, and wherein the liquid supply conduit follows a meandering path including a first air trap section defined at the junction between portions of the conduit extending with upward and downward components respectively, whereby in use once the air vent port is closed, air is displaced along the liquid supply conduit until it is trapped by the first air trap section thereby preventing further liquid flow through the conduit, and wherein the device comprises a second air trap section defined at a second junction between portions of the conduit extending with upward and downward components respectively.2. The liquid sample collection device according to claim 1 , wherein the air vent port is adapted to be ...

Method for Aiding Differential Diagnosis of Stroke

The present invention provides a method of aiding the differential diagnosis of haemorrhagic stroke, ischemic stroke and a transient ischemic attack in a patient who has suffered or is suffering a stroke. The method comprises: (i) determining the concentration of the biomarkers VCAM-1, GFAP and CRP in an ex vivo sample obtained from the patient; and (ii) establishing the statistical significance of the concentration of the biomarkers. Optionally, the method further comprises steps of (iii) determining the concentration of the biomarkers IL-6 and sTNFR1 in an ex vivo sample obtained from the patient; (iv) determining the gender of the patient; and (v) establishing the statistical significance of the concentration of the five biomarkers, in conjunction with the patient's gender. The present invention also provides substrates comprising probes for VCAM-1, GFAP and CRP for use in a method for aiding the differential diagnosis of stroke. 1. A method of aiding the differential diagnosis of haemorrhagic stroke , ischemic stroke and a transient ischemic attack in a patient who has suffered or is suffering a stroke , comprisingi) determining the concentration of the biomarkers VCAM-1, GFAP and CRP in an ex vivo sample obtained from the patient; andii) establishing the statistical significance of the concentration of the biomarkers.2. A method according to claim 1 , further comprisingiii) determining the concentration of the biomarkers IL-6 and sTNFRI in an ex vivo sample obtained from the patient;iv) determining the gender of the patient; andv) establishing the statistical significance of the concentration of the five biomarkers, in conjunction with the patient's gender.3. A method according to claim 1 , wherein each of the biomarker concentration values is inputted into a statistical algorithm or algorithms to produce an output value that correlates with a differential diagnosis of haemorrhagic stroke claim 1 , ischemic stroke or transient ischaemic attack.4. A method ...

Immunoassay for Detecting Kratom, its Constituents and their Use

The invention relates to the field of drug detection and describes antibody-based components methods and kits for the detection and quantification of alkaloids of the plant kratom. The invention is underpinned by novel antibodies which specifically bind to mitragynine alkaloids found in the kratom plant and their metabolites. 1. An antibody which binds specifically to an epitope of one or more of mitragynine , 8-desmethylmitragynine , 8-sulphonylmitragynine , and 8-glucuronidylmitragynine.2. The antibody of which binds specifically to an epitope of mitragynine claim 1 , and 8-desmethylmitragynine.3. The antibody of claim 1 , wherein the antibody has 100% cross-reactivity to mitragynine and greater than 10% cross-reactivity to 8-desmethylmitragynine.5. The antibody of in which W is O.7. The antibody of claim 4 , wherein the antibody has 100% cross-reactivity to mitragynine and greater than 10% cross-reactivity to 8-desmethylmitragynine.9. The method of which detects or quantifies mitragynine and 8-desmethylmitragynine.10. The method of in which the sample is an in vitro human sample claim 8 , preferably selected from blood claim 8 , plasma claim 8 , serum claim 8 , and urine.12. An immunoassay comprising the antibody of . This application claims priority under 35 U.S.C. §119 to United Kingdom Application No 1303168.7 filed Feb. 22, 2013, which is incorporated by reference in its entirety.The invention relates to the field of drug analytics and the detection and quantification of the main constituent of commonly referred to as ‘Kratom’, mitragynine (systematic name: (E)-2-[(2S,3S,12bS)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinozilizin-2-yl]-3-methoxy propenoic acid methyl ester) and its principle metabolite 8-desmethylmitragynine (systematic name: (E)-2-[(2S,3S,12bS)-3-ethyl-8-hydroxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinozilizin-2-yl]-3-methoxy propenoic acid methyl ester—also referred to in the literature as 5-desmethylmitragynine and 9 ...

Ritalinic Acid Immunoassay

The invention provides novel antibodies which specifically bind to the methylphenidate metabolite, ritalinic acid, enabling an immunoassay that can detect methyphenidate in biological samples for an extended period following its ingestion. The invention also describes novel conjugates and kits incorporating the antibodies. 1. An antibody which binds specifically to an epitope of ritalinic acid.2. The antibody of in which the bound epitope comprises the hydroxyl group of ritalinic acid.4. The antibody of in which W of the immunogen is attached to the para position of the benzene ring.5. The antibody of in which W is NH; and n is 0.6. The antibody of in which W is NH; and n is 0.7. The antibody of that has less than 10% cross-reactivity to methylphenidate relative to 100% cross-reactivity to ritalinic acid.8. The antibody of that has less than 1.00% cross-reactivity to methylphenidate relative to 100% cross-reactivity to ritalinic acid.9. The antibody of that has less than 10% cross-reactivity to methylphenidate relative to 100% cross-reactivity to ritalinic acid.10. The antibody of that has less than 1.00% cross-reactivity to methylphenidate relative to 100% cross-reactivity to ritalinic acid.11. The antibody of which is attached to or adsorbed on a substrate.12. The antibody of in which the substrate is a biochip or microtitre plate.13. A method of detecting or quantifying ritalinic acid in an individual claim 1 , the method comprising contacting an in vitro sample taken from the individual with a conjugate and the antibody of claim 1 , detecting the bound conjugate claim 1 , and deducing from a calibrator value or calibrator values the presence or amount of ritalinic acid.14. A method of detecting or quantifying ritalinic acid in an individual claim 3 , the method comprising contacting an in vitro sample taken from the individual with a conjugate and the antibody of claim 3 , detecting the bound conjugate claim 3 , and deducing from a calibrator value or calibrator ...

MEASUREMENT OF FABP FOR DIAGNOSIS

The present invention relates to a multiplexing system comprising a support substrate having immobilised thereto one or more of the following proteins, fragments thereof or a binding molecule, wherein the binding molecule binds specifically to one of the following proteins: E-FABP, B-FABP, IL-FABP, I-FABP, M-FABP, A-FABP, H-FABP, L-FABP or T-FABP. Another aspect is directed to a method for characterising the pattern of FABP antigens existing within a biological sample to reveal information useful in the diagnosis or disease or injury. 1. A multiplexing system comprising a support substrate having immobilised thereon B-FABP , or a peptide fragment thereof , or a binding molecule , said binding molecule binding specifically to B-FABP ,additionally comprising one or more of the proteins, IL-FABP, E-FABP, I-FABP, M-FABP, A-FABP, H-FABP, L-FABP or T-FABP, or a peptide fragment thereof, or a molecule binding specifically thereof.2. The multiplexing system of claim 1 , comprising two or more of the additional binding molecules or proteins claim 1 , or peptide fragments thereof claim 1 , wherein each binding molecule claim 1 , protein claim 1 , or peptide fragment thereof is immobilised to a separate support substrate or on discrete areas of the same support substrate.3. A multiplexing system comprising a support substrate having immobilised thereon two or more of the following proteins: E-FABP claim 1 , B-FABP claim 1 , IL-FABP claim 1 , I-FABP claim 1 , M-FABP claim 1 , A-FABP claim 1 , H-FABP claim 1 , L-FABP or T-FABP claim 1 , or a peptide fragment thereof claim 1 , or two or more binding molecules claim 1 , each of said binding molecules binding specifically to a single different one of said proteins.4. The multiplexing system of or claim 1 , wherein the support substrate is a bead or microparticle or is a planar surface comprising a plurality of discrete reaction zones claim 1 ,wherein each different binding molecule or protein, or peptide fragment thereof, is ...

Opioid Detection

An immunoassay method is described which detects O-desmethyltramadol only. This enables an assay of high sensitivity and specificity avoiding false positive results. The unique antibodies incorporated in the immunoassay method can be combined with antibodies which detect mitragynine to provide an assay which increases the possibility of detecting the commonly found drug combination of O-desmethyltramadol and mitragynine.

Tilidine Immunodetection

An immunoassay for the detection of tilidine and nortilidine is described. The invention also describes antibodies and kits. 2. The method of for detecting or determining tilidine claim 1 , nortilidine and bisnortilidine.3. The method of claim 1 , wherein the one or more antibodies are raised against the immunogen of formula II in which the crosslinker is —X—Y—;wherein, X, which is attached to the nitrogen atom, is selected from the group comprising a substituted or unsubstituted, straight or branched chain, saturated or unsaturated alkylene moiety, or an arylene; and{'sub': '2', 'Y is selected from —C(O)—, —NH—, maleimido, —N—C(O)—, —N—C(S)—, —S—, —S(O)—, and —S(O)—.'}5. The immunogen of in which the crosslinker is —X—Y—;wherein, X, which is attached to the nitrogen atom, is selected from the group comprising a substituted or unsubstituted, straight or branched chain, saturated or unsaturated alkylene moiety, or an arylene; and{'sub': '2', 'Y is selected from —C(O)—, —NH—, maleimido, —N—C(O)—, —N—C(S)—, —S—, —S(O)—, and —S(O)—.'}7. The antibody of wherein the antibody has been raised against the immunogen of formula II in which the crosslinker is —X—Y—;wherein, X, which is attached to the nitrogen atom, is selected from the group comprising a substituted or unsubstituted, straight or branched chain, saturated or unsaturated alkylene moiety, or an arylene; and{'sub': '2', 'Y is selected from —C(O)—, —NH—, maleimido, —N—C(O)—, —N—C(S)—, —S—, —S(O)—, and —S(O)—.'}8. The antibody of claim 6 , wherein the epitope comprises (±)-trans ethyl 2-(amino)-1-phenylcyclohex-3-enylcarboxylate.9. The antibody of claim 6 , wherein the epitope comprises (±)-trans ethyl 2-(amino)-1-phenylcyclohex-3-enylcarboxylate in which the amino is mono or disubstituted with methyl.10. The antibody of which has a cross-reactivity of >10% to nortilidine hydrochloride when compared to 100% for tilidine hydrochloride.11. The antibody of which has a cross-reactivity of >7.5% to bisnortilidine ...

IMMUNOASSAY FOR CYCLOPROPYLINDOLE BASED SYNTHETIC CANNABINOIDS, METABOLITES AND DERIVATIVES THEREOF

The invention relates to the detection and quantification of cyclopropylindole based synthetic cannabinoids UR-144 and XLR-11 by providing antibodies based on novel immunogens. These antibodies can be incorporated into methods and kits for the detection of UR-144, XLR-11 and their metabolites. 2. The antibody of wherein R is selected from H claim 1 , substituted methyl claim 1 , substituted ethyl claim 1 , substituted or unsubstituted propyl claim 1 , substituted or unsubstituted butyl claim 1 , substituted or unsubstituted pentyl claim 1 , and substituted or unsubstituted hexyl.3. The antibody of wherein R is a substituted alkyl group.4. The antibody of wherein R is a substituted pentyl group.5. The antibody of wherein R is selected from pentyl claim 1 , 5-hydroxypentyl claim 1 , 4-hydroxypentyl claim 1 , pentanoic acid claim 1 , and 5-fluoropentyl.6. The antibody of wherein R is pentanoic acid or an amide or ester derivative thereof.7. The antibody of wherein R is a substituted methyl group.8. The antibody of wherein R is a substituted methyl group in which methyl is substituted with substituted or substituted claim 1 , saturated or unsaturated pyran.9. The antibody of wherein R is a substituted methyl group in which methyl is substituted with tetrahydropyran.10. The antibody of which is capable of binding to at least one epitope of an analyte selected from UR-144 claim 1 , UR-144 pentanoic acid claim 1 , UR-144 N-pentanol claim 1 , UR-144 desalkyl and/or XLR-11 and/or metabolites or derivatives thereof.11. The antibody of claim 1 , wherein the antibody has 100% cross-reactivity to UR-144 pentanoic acid and greater than 10% cross-reactivity to UR-144 claim 1 , UR-144 N-pentanol claim 1 , UR-144 desalkyl and XLR-11.12. The antibody of claim 1 , wherein the antibody has 100% cross-reactivity to UR-144 pentanoic acid and greater than 15% cross-reactivity to UR-144 claim 1 , UR-144 N-pentanol claim 1 , UR-144 desalkyl and XLR-11.13. The antibody of claim 1 , wherein ...

KIDNEY DISEASE BIOMARKER

The present invention provides methods and solid state devices for detecting and staging chronic kidney disease in a patient, where the levels of biomarkers in a sample obtained from a patient are elevated or reduced compared to the levels in a sample obtained from healthy subject. 1. A method for detecting kidney disease in a subject , comprising measuring the amount of two or more biomarkers in a sample obtained from the subject , and determining whether the amount of the biomarkers are altered compared to a normal control , wherein at least two of the biomarkers are C3a desArg and MIP 1α.2. A method for determining the efficacy of a treatment for chronic kidney disease , comprising measuring the amount of biomarkers in a sample obtained from a subject receiving such treatment , wherein at least two of the biomarkers are C3a desArg and MIP 1α , and comparing the level of the biomarkers to that of a sample from an untreated control to determine whether the treatment has had the effect of altering the biomarker level , or comparing the level of the biomarkers to those of a sample obtained from the subject before treatment , wherein a reduction or maintenance in the stage of chronic kidney disease or a slowing of progression through stages of chronic kidney disease following treatment indicates that the treatment has been successful.37-. (canceled)8. A method according to or , wherein the kidney disease is chronic kidney disease.9. A method according to claim 8 , wherein the chronic kidney disease is stage 1 claim 8 , stage 2 or stage 3 chronic kidney disease.10. (canceled)11. A method according to or claim 8 , wherein the sample is urine claim 8 , blood claim 8 , plasma claim 8 , serum or saliva.12. A method according to claim 11 , wherein the sample is plasma or serum.13. A method according to or claim 11 , wherein the amount of the biomarker in the sample is measured by binding of an antibody specific for each biomarker.14. A method according to claim 13 , wherein ...

KIDNEY DISEASE BIOMARKER

The present invention provides a method of stratifying a patient suffering from CKD into one of stages 1-3 of CKD, comprising determining the level of the biomarkers FABP1, γ-GT, AST, creatinine and cystatin C in a sample obtained from the patient and comparing the level of FABP1 in the sample to a control value and the levels of γ-GT, AST, creatinine and cystatin C in the sample to a range of control values for each biomarker, wherein an increased level of FABP1 compared to the control value and levels of γ-GT, AST, creatinine and cystatin C within the range of control values for each biomarker indicate that the patient suffers from stage 1 CKD or wherein an increased level of FABP1 compared to the control value, levels of γ-GT and AST within the range of control values for each biomarker, and increased levels of creatinine and cystatin C compared to an upper threshold of the control range for these biomarkers indicate that the patient suffers from stage 2 or stage 3 CKD. 1. A method of stratifying a patient suffering from chronic kidney disease (CKD) into one of stages 1-3 of CKD , comprising determining the level of the biomarkers FABP1 , γ-GT , AST , creatinine and cystatin C in a sample obtained from the patient.2. The method of claim 1 , further comprising the use of a classification algorithm claim 1 , derived using logistic regression claim 1 , decision trees claim 1 , support vector machines claim 1 , neural networks claim 1 , random forest or another machine learning algorithm.3. The method of claim 1 , wherein the level of the biomarkers FABP1 claim 1 , γ-GT claim 1 , AST claim 1 , creatinine and cystatin C in a sample obtained from the patient are compared to a range of control values for each biomarker claim 1 , wherein an increased level of FABP1 compared to a lower threshold of the range of control values of FABP1 and levels of γ-GT claim 1 , AST claim 1 , creatinine and cystatin C within the range of control values for each biomarker indicate that ...

Immunoassay for phenethylamines of the 2c and do sub-families

Immunoassay methods and their requisite components for the detection and determination of phenethylamines of the 2C and DO sub-families are described.

ASSAY FOR THE DETECTION OF THE PHENYLPIPERAZINE FAMILY

The current invention describes novel immunogens which are used in the production of novel antibodies with unique binding properties in that they cross-react with a variety of phenylpiperazine derivatives. These antibodies enable methods and kits to detect and/or determine phenylpiperazine derivatives (for example mCPP, TFMPP and MeOPP) in an in vitro sample which are advantageous over currently available analytical methods in terms of cost, ease of use, speed and sensitivity. 2. An immunogen comprising a hapten of conjugated to an antigenicity-conferring carrier material.3. The immunogen of in which D of -(A)m-B-D is coupled to the antigenicity-conferring carrier material.4. The immunogen of which is either 1-(3-carboxyphenyl)piperazine or 1-(4-carboxymethyletherphenyl)piperazine is coupled to the antigenicity-conferring carrier material.5. The immunogen of in which the antigenicity-conferring carrier material is selected from BTG claim 2 , BSA claim 2 , and KLH.6. An antibody raised against the immunogen of .7. An antibody raised against the 1-(3-carboxyphenyl)piperazine immunogen of having specificity for 1-(3-methylphenyl)piperazine with an IC50 value of around 1 ng/ml claim 4 , which is further characterised by having cross-reactivity to 1-(3-chlorophenyl)piperazine claim 4 , 1-phenylpiperazine claim 4 , 1-(4-methoxyphenyl)piperazine claim 4 , 1-(4-hydroxyphenyl)piperazine claim 4 , 1-(4-fluorophenyl) piperazine claim 4 , 1-(3-hydroxyphenyl)piperazine claim 4 , 1-(3-trifluoromethylphenyl)piperazine and 1-(2-methoxyphenyl)piperazine.8. An antibody raised against the 1-(4-carboxymethyletherphenyl)piperazine immunogen of having specificity for 1-(3-methylphenyl)piperazine with an IC50 value of around 1 ng/ml claim 4 , which is further characterised by having cross-reactivity to 1-(3-chlorophenyl)piperazine claim 4 , 1-phenylpiperazine claim 4 , 1-(4-methoxyphenyl)piperazine claim 4 , 1-(4-hydroxyphenyl)piperazine claim 4 , 1-(4-fluorophenylpiperazine claim 4 , 1-( ...

AH-7921 DETECTION

Antibodies, immunoassay methods and kits for the detection and determination of 3,4,-dichloro-N-[(1-(dimethylamino)cyclohexyl)methyl]benzamide and 3,4,-dichloro-N-[(1-(methylamino)cyclohexyl)methyl]benzamide, as well as the precursory immunogens, are described. 126.-. (canceled)281. The immunogen according to claim , wherein the linker has the formula —(CH)—C(O)— and n=1-6.291. The immunogen according to claim , wherein X is —CH—CH—CH— and Y is —C(O)—.301. An antibody raisable against an immunogen of claim .31. The antibody according to claim 30 , wherein the antibody has a cross-reactivity of 100% to 3 claim 30 ,4-dichloro-N-[(1-(dimethylamino)cyclohexyl)methyl]benzamide and a cross-reactivity of greater than 20% to 3 claim 30 ,4-dichloro-N-[(1-(methylamino)cyclohexyl)-methyl]benzamide.32. The antibody according to claim 30 , wherein the antibody has a cross-reactivity of 100% to 3 claim 30 ,4-dichloro-N-[(1-(dimethylamino)cyclohexyl)methyl]benzamide and a cross-reactivity of greater than 50% to 3 claim 30 ,4-dichloro-N-[(1-(methylamino)cyclohexyl)-methyl]benzamide.33. The antibody according to claim 30 , wherein the antibody has a cross-reactivity of 100% to 3 claim 30 ,4-dichloro-N-[(1-(dimethylamino)cyclohexyl)methyl]benzamide and a cross-reactivity of greater than 20% and less than 100% to 3 claim 30 ,4-dichloro-N-[(1-(methylamino)cyclohexyl)methyl]benzamide.34. The antibody according to claim 30 , wherein the antibody has a cross-reactivity of 100% to 3 claim 30 ,4-dichloro-N-[(1-(dimethylamino)cyclohexyl)methyl]benzamide and a cross-reactivity of greater than 50% and less than 100% to 3 claim 30 ,4-dichloro-N-[(1-(methylamino)cyclohexyl)methyl]benzamide.35. The antibody according to claim 30 , wherein the antibody has an ICof less than 1.00 ng/mL to each of 3 claim 30 ,4-dichloro-N-[(1-(dimethylamino)cyclohexyl)methyl]-benzamide and 3 claim 30 ,4-dichloro-N-[(1-(methylamino)cyclohexyl)methyl]benzamide.36. The antibody according to claim 30 , which has been ...

IMMUNOASSAY

Antibodies, immunoassay methods and kits for the detection and determination of 3,4,-dichloro-N-[2-(dimethylamino)cylohexyl]-N-methylbenzamide and 3,4,-dichloro-N-[2-(methylamino)cylohexyl]-N-methylbenzamide, as well as the precursory immunogens, are described. 2. The immunogen of in which the crosslinker is a substituted or unsubstituted claim 1 , saturated or unsaturated alkylene moiety of chain length C.3. The immunogen of in which the substituted or unsubstituted claim 2 , saturated or unsaturated alkylene moiety has a chain length of C.4. The immunogen of in which the crosslinker is —CH—CH—C(O)—.5. Antibodies raised to an immunogen of .6. The antibodies of further characterised in having a cross-reactivity of 100% to 3 claim 5 ,4-dichloro-N-[2-(dimethylamino)cylohexyl]-N-methylbenzamide and a cross-reactivity of >10% to 3 claim 5 ,4-dichloro-N-[(2-(methylamino)cylohexyl]-N-methylbenzamide.7. The antibodies of claim 5 , wherein the antibodies have an ICof <5.00 ng/ml to 3 claim 5 ,4-dichloro-N-[2-(dimethylamino)cylohexyl]-N-methylbenzamide.8. An immunoassay method of detecting or determining 3 claim 5 ,4-dichloro-N-[2-(dimethylamino)cylohexyl]-N-methylbenzamide and 3 claim 5 ,4-dichloro-N-[2-(methylamino) cylohexyl]-N-methylbenzamide in a solution or an in vitro sample taken from an individual with one or more detecting agents and an antibody of ; measuring the signal or signals produced by the one or more detecting agents; and deducing the presence of claim 5 , or amount of claim 5 , 3 claim 5 ,4-dichloro-N-[2-(dimethylamino)cylohexyl]-N-methyl benzamide and 3 claim 5 ,4-dichloro-N-[2-(methylamino)cylohexyl]-N-methylbenzamide.9. A substrate comprising an antibody of .10. The substrate of claim 9 , wherein the substrate is a microtitre plate or a biochip.11. The substrate of claim 10 , wherein the biochip is a ceramic biochip.12. A kit comprising an antibody of . This application claims priority under 35 U.S.C. § 119 to Great Britain Application No. 1702907.5, ...

RELATING TO SUBSTRATES FOR THE ATTACHMENT OF MOLECULES

A substrate comprising a coating of a masking material, and a plurality of discrete reaction zones onto which one or more binding agents are intended to be attached, wherein said zones are uncoated areas on the substrate. 120-. (canceled)21. A ceramic substrate comprising a coating of a masking material , and a plurality of discrete reaction zones onto which one or more binding agents are intended to be attached , wherein said zones are uncoated areas on the substrate , wherein the masking material comprises one or more resins and has a contact angle of 60-120° , and the ceramic substrate has a particle size of 1 to 30 μm.22. A ceramic substrate according to claim 21 , wherein the ceramic substrate has a particle size of less than 20 μm.23. A ceramic substrate according to claim 21 , wherein the ceramic substrate has a particle size of less than 10 μm.24. A ceramic substrate according to claim 21 , wherein the ceramic substrate consists of 96% alumina (AlO) with a particle size of 4 to 8 μm.25. A ceramic substrate according to claim 21 , wherein the substrate is approximately 100 mm×99 mm in size claim 21 , and wherein the substrate comprises square subsections that are approximately 9 mm×9 mm in size claim 21 , each square subsection comprising a grid of discrete reaction zones claim 21 , and wherein each square subsection comprises a grid of from 5×5 claim 21 , to 30×30 discrete reaction zones.26. A ceramic substrate according to claim 21 , wherein the density of the discrete reaction zones is in the range of from 0.08 to 15 zones/mm.27. A ceramic substrate according to claim 21 , wherein each discrete reaction zone has a diameter ranging from 0.1 mm to 1 mm in diameter.28. A ceramic substrate according to comprising one or more binding agents immobilised on the discrete reaction zones.29. A ceramic substrate according to claim 21 , wherein the substrate is a white ceramic substrate.30. A ceramic substrate according to claim 21 , wherein the contact angle is 90°- ...

IMMUNOASSAY FOR PREGABALIN

Antibodies, immunoassay methods and kits thereof are described for the detection and determination of 3-(aminomethyl)-5-methylhexanoic acid. The novel immunogens from which said antibodies are generated are also described. 2. The immunogen of claim 1 , wherein:X is -A-B-D-;A is a functional group or heteroatom attaching the crosslinker to the hapten;{'sub': '1-6', 'B is a C, substituted or unsubstituted alkylene moiety optionally incorporating an optionally substituted cycloalkyl, an optionally substituted heterocyclyl or an optionally substituted heteroaryl moiety; and'}D is a functional group or heteroatom attaching the crosslinker to the antigenicity-conferring carrier material.3. The immunogen of claim 2 , wherein:A is —O—, —NH— or —S—;D is —C(O)—, —NH—, —C═, or —S—; and{'sub': '1-6', 'B is a C, substituted or unsubstituted alkylene moiety optionally incorporating an optionally substituted heterocyclic or an optionally substituted heteroaryl moiety.'}4. The immunogen of wherein the accm is selected from the group consisting of bovine thyroglobulin claim 1 , bovine serum albumin claim 1 , keyhole limpet haemocyanin claim 1 , bovine gamma globulin and egg ovalbumin.5. An antibody rasiable against an immunogen of .6. The antibody of further characterised in having a cross-reactivity of 100% to pregabalin.7. The antibody of further characterised in having a cross-reactivity of 100% to pregabalin and a cross-reactivity of <5% to at least one of 1 claim 5 ,3-dimethylamylamine (DMAA) claim 5 , Vigabatrin claim 5 , Felbamate claim 5 , Retigabine claim 5 , Lacosamide claim 5 , Stiripentol claim 5 , Acetylcholine claim 5 , D-Glutamic Acid claim 5 , L-Glutamic Acid claim 5 , Tiagabine HCl claim 5 , Gamma-Aminobutyric Acid claim 5 , N-methylpregabalin claim 5 , Valporic Acid claim 5 , Levetiracetam claim 5 , Topiramate claim 5 , Serotonin claim 5 , Carbamazepine claim 5 , Gabapentin claim 5 , and Phenobarbital.8. The antibody of further characterised in having an IC50 of ...

PIPETTE TIP DISPOSAL ASSEMBLY

There is provided a pipette tip disposal assembly. The assembly comprises a receiving element adapted to support an end of at least one pipette tip, the at least one pipette tip being toppled in use from the receiving element along a first direction; and a container positioned to receive the at least one toppled pipette tip, the at least one pipette tip falling towards a base of the container on being received by the container. The base of the container has a first linear dimension aligned with the first direction corresponding to the length of a pipette tip. 1. A pipette tip disposal assembly comprising:a receiving element adapted to support an end of at least one pipette tip, the at least one pipette tip being toppled in use from the receiving element along a first direction; anda container positioned to receive the at least one toppled pipette tip, the at least one pipette tip falling towards a base of the container on being received by the container,wherein said base of the container has a first linear dimension aligned with the first direction corresponding to the length of a pipette tip.2. The pipette tip disposal assembly of claim 1 , wherein the receiving element is at a separation of no more than three times the first linear dimension from the base of the container.3. The pipette tip disposal assembly of claim 1 , wherein the receiving element is at a separation of no less than half the first linear dimension from the base of the container.4. The pipette tip disposal assembly of claim 1 , wherein the receiving element comprises a planar portion.5. The pipette tip disposal assembly of claim 4 , wherein the planar portion of the receiving element is at an angle with respect to the horizontal plane.6. The pipette tip disposal assembly of claim 5 , wherein the angle is 2 degrees (°).7. The pipette tip disposal assembly of claim 1 , wherein the receiving element and the container are connected.8. The pipette tip disposal assembly of claim 7 , wherein the ...

GFAP DERIVATIVES FOR STROKE DIAGNOSTICS

Described are methods and kits for diagnosing stroke using GFAP derivatives. 1. An immunoanalytical method of diagnosing or supporting the diagnosis of stroke in a subject comprising taking a sample from the subject and measuring the amount of a GFAP derivative present in the sample the method incorporating an antibody which binds to an epitope incorporated in the sequence ETRASERAEMME of a GFAP derivative , in which an amount of a GFAP derivative in the sample bound by the antibody which is greater than the amount of a GFAP control is indicative of stroke.2. The method of in which the stroke is haemorrhagic stroke claim 1 , haemorrhagic transformation or fatal ischaemic stroke.3. The method of in which the GFAP control level is one that has been measured in a healthy patient or a healthy population of patients claim 1 , or has been derived from a population of patients categorised as one or more of TIA claim 1 , stroke mimic or ischaemic stroke.4. A method comprising using GFAP derivatives as markers of haemorrhagic stroke claim 1 , haemorrhagic transformation or fatal ischaemic stroke.5. The method of in which the GFAP derivative has a molecular weight of about 44 kDa and which is bound by an antibody which recognises the epitope sequence ETRASERAEMME within the GFAP derivative.6. The method of in which the antibody binds to at least one amino acid within the sequence SERA of the GFAP derivative.7. An antibody which binds to an epitope of a GFAP species incorporated in the sequence ETRASERAEMME.8. The antibody of in which the epitope comprises a least one amino acid from the sequence SERA.9. The antibody of in which the GFAP species is a GFAP derivative of molecular weight less than native GFAP without post translational modification and has a molecular weight of about 44 kDa.10. The antibody of which is attached to or adsorbed on the surface of a solid-state device.11. The antibody of in which the solid-state device is a biochip.12. A method comprising using an ...

IMMUNOASSAY FOR COMPOUNDS OF THE NBOMe FAMILY

An immunoassay method for detecting and determining ‘NBOMe’ family designer drugs is described. Also described are components for use in implementing the method, namely, antibodies, detection agents, solid state devices and kits as well as immunogens used to raise the antibodies. 1. An immunoassay method of detecting or determining phenethylamines of the NBOMe sub-family comprising; contacting a solution or an in vitro sample taken from an individual , suspected of containing phenethylamines , with one or more detecting agents and an antibody specific to phenethylamines of the NBOMe sub-family , measuring the signal or signals produced by the one or more detecting agents , and deducing from a calibration curve the presence of , or amount of phenethylamines of the NBOMe sub-family in said sample.3. (canceled)5. (canceled)6. The immunoassay method of wherein the antibody is derived from an immunogen comprising 25NH2-NBOMe conjugated to an antigenicity-conferring carrier material.7. (canceled)8. The immunoassay method of wherein the antigenicity-conferring carrier material is selected from bovine serum albumin (BSA) claim 4 , egg ovalbumin claim 4 , bovine gamma globulin claim 4 , bovine thyroglobulin (BTG) claim 4 , keyhole limpet haemocyanin (KLH) claim 4 , synthetic poly(amino acids) having a sufficient number of available amino groups claim 4 , lysine claim 4 , and synthetic or natural polymeric materials bearing reactive functional groups.9. (canceled)12. The antibody of claim 11 , in which claim 11 , in the epitope of Structure (Y′){'sup': '1', 'Ris selected from a halogen (optionally selected from iodo or bromo), propyl, methoxy, methyl, ethyl, hydrogen, nitro, ethylthio, propylthio and isopropylthio; and'}{'sup': '2', 'Ris methoxy.'}13. The antibody of claim 11 , in which substances of the epitope of Structure (Y′) show a cross reactivity of 75 to 200% when compared to 100% for 25I-NBOMe.HCl.14. The antibody of claim 10 , which binds to an epitope of at least ...

IMMUNOASSAY FOR SYNTHETIC CANNABINOIDS OF THE ADAMANTYL INDAZOLE/INDOLE-3-CARBOXAMIDE FAMILY

An immunoassay method for detecting and determining adamantane substituted indazole and indole synthetic cannabinoids is described. Also described are components for use in implementing the method, namely, antibodies, detection agents, solid state devices and kits as well as immunogens used to raise the antibodies. 4. (canceled)6. (canceled)8. (canceled)9. (canceled)10. (canceled)11. (canceled)13. The antibody of in which claim 12 , in the epitope of Structure C claim 12 , the halogen is F claim 12 , Br claim 12 , I or Cl claim 12 , optionally F.14. The antibody of in which claim 12 , in the epitope of Structure C claim 12 , Y is CH claim 12 , Z is OH claim 12 , n is an integer from 1 to 3 (optionally 1) claim 12 , and X is halogen.15. (canceled)16. The antibody of in which claim 12 , in the epitope of Structure C claim 12 , alk is a substituted or unsubstituted pentyl group andi) Y is N, Z is H and X is H or halogen,ii) Y is CH, Z is OH, n is an integer from 1 to 3 (optionally 1), and X is halogen oriii) Y is N, Z is OH, n is an integer from 1 to 3 (optionally 1), and X is H or halogen.17. The antibody of in which claim 12 , in the epitope of Structure C claim 12 , alk is a substituted or unsubstituted pentyl group andi) Y is N, Z is H and X is H or halogen, orii) Y is N, Z is OH, n is an integer from 1 to 3 (optionally 1), and X is H or halogen.19. The antibody of in which claim 18 , in the epitope of Structure C′ claim 18 , Z is OH and/or in which claim 18 , in the epitope of Structure C′ claim 18 , the halogen is F claim 18 , Br claim 18 , I or Cl claim 18 , optionally F.20. The antibody of in which claim 18 , in the epitope of Structure C or C′ claim 18 , Y is CH claim 18 , Z is OH claim 18 , and X is halogen.21. The antibody of in which claim 18 , in the epitope of Structure C′ claim 18 , alk is a substituted or unsubstituted pentyl group.22. The antibody of in which claim 18 , in the epitope of Structure C′ claim 18 , alk is a substituted or unsubstituted ...

Fluidic card for analysis of biochips

The biochip (3) is at least partially located in the chamber. A seal (7) is provided for sealing the biochip in the chamber (2) when the biochip is urged into the chamber. The fluidic channel has a serpentine form.

MT-45 IMMUNODETECTION

Components for enabling immunodection of MT-45 are described including immunogens, antibodies derived from the immunogens, immunoassay methods, detecting agents and kits. 2. The immunogen of claim 1 , wherein R is attached to the meta or para position of the phenyl ring.3. The immunogen of claim 2 , wherein:R is -(Q)m-Y—X—, wherein:Q or Y (if Q is not present) is attached to the meta or para position of the phenyl ring;m=0 or 1;Y is a substituted or unsubstituted, straight or branched chain alkanediyl moiety, a substituted or unsubstituted, saturated or unsaturated cycloalkylene moiety, or a substituted or unsubstituted arylene moiety;X, before attachment to the antigenicity conferring carrier material, is carboxy, dithiopyridyl, maleimidyl, amino, hydroxyl, thiol, thioester, or aldehyde; and{'sub': '2', 'Q is —O—, —S—, —NH—, —C(O)—, —C(O)—O—., —S(O)—, —S(O)—, —C(S)—O— or —C(O)—S—.'}4. The immunogen of claim 3 , wherein:m=1;Q is —O—, —NH— or —S—; and{'sub': '1-6', 'Y is a Csubstituted or unsubstituted, straight chain, saturated alkanediyl moiety.'}5. The immunogen of claim 4 , wherein Q is attached to the meta position of the phenyl ring.6. The immunogen of claim 1 , wherein the antigenicity conferring carrier material is keyhole limpet haemocyanin claim 1 , bovine thyroglobulin claim 1 , bovine serum albumin claim 1 , egg ovalbumin claim 1 , bovine gamma globulin or cationised BSA.7. An antibody raisable from an immunogen of .8. The antibody of claim 7 , wherein the antibody binds to MT-45.10. An immunoassay method of detecting or determining MT-45 in an in vitro sample or in a solution comprising:{'claim-ref': {'@idref': 'CLM-00007', 'claim 7'}, 'contacting the sample or solution with a detecting agent and an antibody of ;'}detecting the amount of detecting agent bound to the antibody; anddeducing the presence or amount of MT-45.12. The immunoassay method of claim 11 , wherein R″ is attached to the meta position of the phenyl ring.13. The immunoassay method of ...

SUBSTRATES FOR THE ATTACHMENT OF MOLECULES

A substrate comprising a coating of a masking material, and a plurality of discrete reaction zones onto which one or more binding agents are intended to be attached, wherein said zones are uncoated areas on the substrate. 1. A substrate comprising a coating of a masking material and a plurality of discrete reaction zones onto which one or more binding agents are intended to be attached , wherein said zones are uncoated areas on the substrate , wherein the masking material comprises one or more resins and has a contact angle of 60-120°.2. A substrate according to claim 1 , wherein the substrate is approximately 100 mm×99 mm in size claim 1 , and wherein the substrate comprises square subsections that are approximately 9 mm×9 mm in size claim 1 , each square subsection comprising a grid of discrete reaction zones claim 1 , andwherein each square section comprises a grid of from 5×5, 10×10, 20×20, or 30×30 discrete reaction zones.3. A substrate according to claim 1 , wherein the density of the discrete reaction zones is in the range of from 0.08 to 15 zones/mm.4. A substrate according to claim 1 , wherein each discrete reaction zone has a diameter ranging from 0.1 mm to 1 mm in diameter.5. A substrate according to claim 1 , comprising one or more binding agents immobilised on the discrete reaction zones.6. A substrate according to claim 1 , wherein the substrate comprises silicon claim 1 , metal oxides claim 1 , ceramic claim 1 , glass or plastic claim 1 , preferably wherein the substrate is ceramic claim 1 , glass or plastic.7. A substrate according to claim 1 , wherein the contact angle is 90°-120°.8. A substrate according to claim 1 , wherein the thickness of the coating applied to the substrate is 2 to 50 μm (micron) thick.9. A substrate according to claim 1 , wherein the coating of masking material is a color ranging from off-white to black.10. A substrate according to claim 1 , wherein the discrete reaction zones are chemically activated to allow immobilisation ...

BIOCHIP STORAGE WELLS

The present invention is directed to a cap for a biochip storage well. The cap comprises a resilient sealant layer capable, under the application of pressure, of forming a vapour-proof seal with a line contact interface formation extending around the perimeter of a biochip storage well. 111-. (canceled)12. An assay assembly comprising a biochip storage well having a base and one or more side walls , adapted to receive a biochip , with a line contact interface formation facing away from the base and extending along an upwardly facing perimeter of the wall(s) and a cap comprising a resilient sealant layer , wherein a vapour-proof seal can be formed between the resilient sealant layer of the cap and the line contact interface formation of the biochip storage well , when the resilient sealant layer of the cap is applied , under pressure , against the line contact interface formation.13. The assay assembly according to claim 12 , wherein the line contact interface formation is in the form of a knife-edge.14. The assay assembly according to claim 12 , wherein the pressure applied is in the range of 10-50 N.1516-. (canceled)17. A method of sealing the assay assembly of claim 12 , comprising the steps of:placing the cap onto the biochip storage well wall so that the resilient sealant layer is above the line contact interface formation;applying external force onto the cap so that the cap closes the biochip storage well and the resilient sealant layer is pressed into the line contact interface formation, forming a vapour-proof seal.18. The method of claim 17 , wherein the biochip storage well has a corresponding flange extending along the perimeter of the biochip storage well and wherein the cap slides onto the corresponding flange extending along the perimeter of the biochip storage well so as to form a vapour-proof seal with the line contact interface formation of the biochip storage well.19. The method according to claim 17 , wherein the pressure applied is in the range of ...

RELATING TO SUBSTRATES FOR THE ATTACHMENT OF MOLECULES

A substrate comprising a coating of a masking material, and a plurality of discrete reaction zones onto which one or more binding agents are intended to be attached, wherein said zones are uncoated areas on the substrate. 1. A substrate comprising a thermally cured coating of a masking material , and a plurality of discrete reaction zones onto which one or more binding agents are intended to be attached , wherein said zones are uncoated areas on the substrate , wherein the masking material comprises one or more resin and has a contact angle of 60-120°.2. A substrate according to claim 1 , wherein the coating has been thermally cured at a temperature of at least 140° C.3. A substrate according to claim 1 , wherein the substrate is approximately 100 mm×99 mm in size claim 1 , and wherein the substrate comprises square subsections that are approximately 9 mm×9 mm in size claim 1 , each square subsection comprising a grid of discrete reaction zones claim 1 , and wherein each square subsection comprises a grid of from 5×5 claim 1 , 10×10 claim 1 , 20×20 claim 1 , or 30×30 discrete reaction zones.4. A substrate according to claim 1 , wherein the density of the discrete reaction zones is in the range of from 0.08 to 15 zones/mm.5. A substrate according to claim 1 , wherein each discrete reaction zone has a diameter ranging from 0.1 mm to 1 mm in diameter.6. A substrate according to comprising one or more binding agents immobilised on the discrete reaction zones.7. A substrate according to claim 1 , wherein the substrate comprises silicon claim 1 , metal oxides claim 1 , ceramic claim 1 , glass or plastic.8. A substrate according to claim 1 , wherein the contact angle is 90°-120°.9. A substrate according to claim 1 , wherein the thickness of the coating applied to the substrate is 2 to 50 μm (micron) thick.10. A substrate according to claim 1 , wherein the coating of masking material is a colour ranging from off-white to black.11. A substrate according to claim 1 , wherein ...

GFAP ACCUMULATING IN STROKE

The use of glial fibrillary acidic protein as a marker of pernicious stroke is described 1. A method of predicting or diagnosing pernicious stroke in a suspected stroke patient comprising , ≤24 hours from admission or symptom onset measuring the amount of glial fibrillary acidic protein in a biological sample taken from the patient and subjecting the patient to a brain scan and , if glial fibrillary acidic protein value is normal and the brain scan negative for haemorrhagic stroke , at ≥24 hours from admission or symptom onset taking a further sample from the patient and measuring the amount of glial fibrillary acidic protein , in whicha high glial fibrillary acidic protein level and a brain scan positive for haemorrhagic stroke ≤24 hours from admission or symptom onset indicates haemorrhagic strokea high glial fibrillary acidic protein level and a brain scan negative for haemorrhagic stroke ≤24 hours from admission or symptom onset indicates fatal ischemic strokea normal glial fibrillary acidic protein level and brain scan negative for haemorrhagic stroke on admission and a high glial fibrillary acidic protein level ≥24 hours from admission or symptom onset indicates haemorrhagic transformation.2. The method of in which the normal glial fibrillary acidic protein level is one that has been measured in a healthy patient or a healthy population of patients claim 1 , or has been derived from a population of patients categorised as one or more of TIA claim 1 , stroke mimic or ischemic stroke.3. The method of in which the second glial fibrillary acidic protein measurement is taken at 24-96 hours from admission or from symptom onset.4. The method of in which a glial fibrillary acidic protein level ≥3 times claim 1 , preferably ≥4 times a healthy control value or a non-pernicious stroke standard value is indicative of pernicious stroke.5. A method of using glial fibrillary acidic protein as a marker of pernicious stroke.6. The method according to together with a brain scan ...

BOVINE PATHOGEN ARRAY

The current invention provides a multiplex method for screening bovine samples for antibodies against several important pathogens. These pathogens include Bovine Viral Diarrhoea Virus (BVDV), Bovine Herpesvirus-1 (BoHV-1), paratuberculosis (MAP), species, and . This multiplex screening is enabled by substrates with immobilized pathogen antigens and offer multiple advantages for the routine testing of farm animals. 1MycobacteriumLeptospiraNeospora caninumFasciola hepatica. A method for screening a bovine sample for antibodies against two or more pathogens , said method comprising; (a) contacting the bovine sample with a substrate onto which is immobilized two or more antigens of two or more pathogens selected from the list consisting of Bovine Viral Diarrhoea Virus (BVDV) , Bovine Herpesvirus-1 (BoHV-1) , paratuberculosis (MAP) , a species , and (b) washing off unbound sample (c) detecting any antibodies in the sample which are bound to the immobilized antigens on the substrate using a labelled detector antibody.2MycobacteriumLeptospiraNeospora caninumFasciola hepatica. The method of claim 1 , wherein the BVDV antigen is one or more of NS3 claim 1 , Ems and E2 claim 1 , the BoHV-1 antigens are glycoprotein B and glycoprotein E claim 1 , the paratuberculosis antigen is Protoplasmic Antigen claim 1 , the antigen is LipL32 claim 1 , the antigens are SRS2 and SAG1 and the antigen is Cathepsin L1.3Mycobacterium. The method of claim 1 , wherein the pathogens include at least BVDV claim 1 , BoHV-1 and paratuberculosis.4Neospora caninum.. The method of claim 1 , wherein the pathogens include at least BVDV claim 1 , BoHV-1 and5Neospora caninumLeptospira. The method of claim 1 , wherein the pathogens include at least BVDV claim 1 , and a species.6. The method of claim 1 , wherein the detector antibody is an anti-IgG or anti-IgM antibody.7. The method of claim 6 , wherein the detector antibody is labelled with Horseradish peroxidase (HRP).8. The method of claim 1 , wherein the ...

Device and apparatus for the simultaneous detection of multiple analytes

Gfap derivatives for stroke diagnostics

Described are methods and kits for diagnosing stroke using GFAP derivatives.

Method and apparatus for analysing an image

A method of analysing an image to obtain an image value. The image comprises a defined array of pixel values. The method comprises (1) determining the highest pixel value in the image; (2) calculating a lower threshold pixel value from the highest pixel value determined in step (1) in accordance with a predetermined algorithm; and (3) obtaining the image value by statistically analysing the pixel values in the image which lie in a range defined by the lower threshold pixel value calculated in step (2).

Improvements relating to substrates for the attachment of molecules

A substrate comprising a coating of a masking material, and a plurality of discrete reaction zones onto which one or more binding agents are intended to be attached, wherein said zones are uncoated areas on the substrate.

Processing instrument for test devices

Haptens, immunogens, antibodies and conjugates for 2-oxo-3-hydroxy LSD

Kidney disease biomarker

The present invention provides a method of stratifying a patient suffering from CKD into one of stages 1-3 of CKD, comprising determining the level of the biomarkers FABP1, ?-GT, AST, creatinine and cystatin C in a sample obtained from the patient and comparing the level of FABP1 in the sample to a control value and the levels of ?-GT, AST, creatinine and cystatin C in the sample to a range of control values for each biomarker, wherein an increased level of FABP compared to the control value and levels of ?-GT, AST, creatinine and cystatin C within the range of control values for each biomarker indicate that the patient 10 suffers from stage 1 CKD or wherein an increased level of FABP1 compared to the control value, levels of ?-GT and AST within the range of control values for each biomarker, and increased levels of creatinine and cystatin C compared to an upper threshold of the control range for these biomarkers indicate that the patient suffers from stage 2 or stage 3 CKD.1

Device and apparatus for the simultaneous detection of multiple analytes

Immunoassay for pyrrolidinophenones

Dried tetramethoxysilane sol-gel containing a leachable reagent

First and second reactants that give a signal when mixed in the presence of an analyte in a liquid sample, are separately contained in sol-gels that release the reactants in the presence of the liquid. For example, when the first and second reactants respectively comprise an oxidant and a reductant, and the reaction provides a detectable signal, the system can be used to detect the presence of contaminants in a water sample. The sol-gel may be obtained by reaction of water with, per part by volume thereof, at least 2 parts of a metal alkoxide, and drying the resultant gel.

Generic binding antibodies with multiple applications

Inmunógeno de estructura**Fórmula** en la que el accm es un material portador que confiere antigenicidad. Structure immunogen ** Formula ** in which accm is an antigenic-conferring carrier material.

Liquid dispensing apparatus

Liquid dispensing apparatus comprises a support member which supports a movably mounted dispensing member. The support member is movable between first and second positions. A single drive system causes the dispensing member to move relative to the support member to a number of dispense positions while the support member is in its first position and causes the support member to move to the second position.

Imaging method for arrayed molecules

A method for imaging molecules contained in an array of discrete reaction sites on the surface of a solid support comprises: (i) imaging the array and detecting a first molecule located on the solid support at a known position with respect to the array; (ii) by reference to the first molecule, aligning inspection windows in registration with the discrete reaction sites; and (iii) determining the amount of detectable signal in each window. The method is used to locate the reaction site; accurately on the array, and to correct for any misalignments.

Assay device processing instrument

An assay device processing instrument comprises a plurality of processing modules. A transport system transports an assay device to each processing module, the transport system being adapted to transfer the assay device from the transport system to the module to enable the transport system to transport another assay device while the first is processed by the processing module. A control system controls operation of the transport system such that each assay device is transferred between the modules in a predetermined sequence, and such that a number of assay devices can be processed in different modules simultaneously.

Phenethanolamine-derived haptens, immunogens and conjugates comprising them and antibodies recognising said immunogenes and conjugates

The present invention relates to a method for preparing haptens of formulae I and II that are useful in the preparation of immunogens, antibodies and conjugates, for use in competitive immunoassays for the detection of ractopamine, isoxsuprine and ritodrine. The haptens are prepared by reacting a phenylethanolamine derivative of formula D with a phenylalkylcarbonyl derivative of formula E: in which, in formula I, Z 1 is a crosslinker and Z 2 is H and, in formula II, Z 1 is H and Z 2 is a crosslinker.

Haptens, immunogens and antibodies to oxycodone and its metabolites

Method for aiding differential diagnosis of stroke

The present invention provides a method of aiding the differential diagnosis of haemorrhagic stroke, ischemic stroke and a transient ischemic attack in a patient who has suffered or is suffering a stroke. The method comprises: (i) determining the concentration of the biomarkers VCAM-1, GFAP and CRP in an ex vivo sample obtained from the patient; and (ii) establishing the statistical significance of the concentration of the biomarkers. Optionally, the method further comprises steps of (iii) determining the concentration of the biomarkers IL-6 and sTNFR1 in an

Immunoassay for pyrrolidinophenones

The invention describes antibodies that bind molecules of the pyrrolidinophenone class of synthetic drugs. The antibodies are derived from novel chemical intermediates, haptens and immunogens and are used in methods and kits to detect and quantify pyrrolidinophenones.

Kidney disease biomarker

The present invention provides methods and solid state devices for detecting and staging chronic kidney disease in a patient, where the levels of biomarkers in a sample obtained from a patient are elevated or reduced compared to the levels in a sample obtained from healthy subject. The invention also relates to the use of methods and solid state devices for measurement of specific biological markers for determining the efficacy of a treatment for chronic kidney disease and for determining a drug treatment protocol for a subject suffering from chronic kidney disease.

Immunodetection and quantification of pyrazolopyrimidine sedatives

The invention relates to novel immunogens, antibodies, methods and kits for use in immunoassays to detect and quantify zaleplon, metabolites of zaleplon and indiplon. These are the first described immunoassays for these compounds and have greater sensitivity than alternative analytical techniques.

Haptens, immunogens, antibodies and conjugates to ketamine and its metabolites

The invention provides haptens, immunogens comprising such haptens coupled to an antigenicity-conferring carrier material, conjugates comprising such haptens bonded to a labelling agent as well as, antibodies raised against such immunogens and capable of binding with ketamine and its primary metabolite, norketamine.

Assay device processing instrument

An assay device processing instrument comprises a plurality of processing modules. A transport system transports an assay device to each processing module, the transport system being adapted to transfer the assay device from the transport system to the module to enable the transport system to transport another assay device while the first is processed by the processing module. A control system controls operation of the transport system such that each assay device is transferred between the modules in a predetermined sequence, and such that a number of assay devices can be processed in different modules simultaneously.

Method and apparatus for analysing an image

A method of analysing an image to obtain an image value. The image comprises a defined array of pixel values. The method comprises (1) determining the highest pixel value in the image; (2) calculating a lower threshold pixel value from the highest pixel value determined in step (1) in accordance with a predetermined algorithm; and (3) obtaining the image value by statistically analysing the pixel values in the image which lie in a range defined by the lower threshold pixel value calculated in step (2).

Manufacture of Array Chips

The present invention relates to a method of manufacturing an array chip, comprising the steps of: i) depositing at least one ligand onto the active surface of a wafer substrate, having at least one scribe line, the active surface being the reverse of the surface comprising the at least one scribe line; ii) detecting the ligand in relation to the at least one scribe line; and iii) breaking the wafer substrate along the at least one scribe line, to produce at least one array chip.

Improvements to stroke diagnosis

Change of reference standards leads to improved biomarker-based methods of stroke diagnosis.

DEVICE AND DEVICE FOR THE SIMULTANEOUS DETECTION OF VARIOUS ANALYTICS.

DISPOSITIVO DE ESTADO SOLIDO PARA REALIZAR ENSAYOS MULTIANALITICOS, QUE COMPRENDE UN SUSTRATO Y VARIAS ZONAS DE REACCION DISCRETAS, SOPORTANDO CADA UNA UN LIGANDO UNIDO COVALENTEMENTE AL SUSTRATO, SIENDO LA SUPERFICIE DEL SUSTRATO ENTRE LAS ZONAS DE REACCION INERTE ANTE EL ANALITICO. ESTE DISPOSITIVO PUEDE OBTERNERSE MEDIANTE UN PROCESO DE ACTIVACION DE LA SUPERFICIE DEL SUSTRATO Y APLICANDO UNA MATRIZ DE LIGANDOS EN AREAS DISCRETAS SOBRE LA SUPERFICIE. SOLID STATE DEVICE FOR MULTI-ANALYTIC TESTS, WHICH INCLUDES A SUBSTRATE AND VARIOUS DISCRETE REACTION AREAS, SUPPORTING EACH BINDING COVALENTLY TO SUBSTRATE, BEING THE SURFACE OF THE SUBSTRATE BETWEEN THE REINFORCEMENT AREA. THIS DEVICE CAN BE OBTAINED BY MEANS OF A PROCESS OF ACTIVATION OF THE SUBSTRATE SURFACE AND APPLYING A MATRIX OF LIGANDS IN DISCRETE AREAS ON THE SURFACE.

Method for making a device for the simultaneous detection of multiple analytes

A solid state device for performing multi-analyte assays, comprises a substrate and a multiplicity of discrete reaction sites each bearing a ligand covalently bonded to the substrate, wherein the surface of the substrate between the reaction sites is inert with respect to analyte. Such a device may be obtained by a process of activating the surface of the substrate, and applying an array of ligands on to discrete areas on the surface.

Chronic kidney disease biomarker

Method and apparatus for analysing an image

Multi-analyte immunoassay

An assay for an analyte in a sample, wherein the sample is contacted with an array of ligands including a ligand specific for the analyte, additionally comprises including a scavenger material that binds the analyte and thereby reduces its available concentration.

Simultaneous detecting device for plural analysis matter, and equipment

(57)【要約】 【課題】 複数の分析物を、同時に短時間で同定・定量 する。 【解決手段】 基体ならびに多数の独立した反応部位を 有して成り、各反応部位は基体に共有結合的に固定され たリガンドを有し、反応部位間の基体表面は分析物に対 して不活性である複数の分析物のアッセイを実施するた めの固体状態のデバイス。このデバイスは、基体の表面 を活性化させた後、基体表面の独立した部位に、リガン ドのアレイを適用する方法により得られる。

Pcr cartridge

A cartridge for polymerase chain reaction, PCR, comprises a vessel for PCR having an opening and a resealable membrane arranged, in use, to cover the opening of the vessel such that the opening of the vessel is vapour tight.

Device and apparatus for the simultaneous detection of multiple analytes

A solid state device for performing multi-analyte assays, comprises a substrate and a multiplicity of discrete reaction sites each bearing a ligand covalently bonded to the substrate, wherein the surface of the substrate between the reaction sites is inert with respect to analyte. Such a device may be obtained by a process of activating the surface of the substrate, and applying an array of ligands on to discrete areas on the surface.

Improved immunoassay for pyrrolidinophenones

An improved immunoassay is disclosed for the detection and determination of pyrrolidinophenone based designer drugs in biological fluids (Urine, Blood, Oral fluid and Hair). The generic immunoassay is underpinned by novel, sub-family-specific antibodies which display surprising sensitivity. Further described are substrates comprising an antibody that is specific to compounds of the pyrrolidinophenone family. Also described are the novel immunogens from which the antibodies are derived and kits incorporating the antibodies of the current invention.

Methoxetamine assay

U-47700 immunoassay

Method and apparatus for analysing an image

Assay for methoxetamine

Components for enabling immunodetection of methoxetamine are described including immunogens, haptens, antibodies and kits.

Improved immunoassay for pyrrolidinophenones

Gfap accumulating in stroke

Immunoassay for detecting kratom its constituents and their use

The invention relates to the field of drug detection and describes antibody-based components methods and kits for the detection and quantification of alkaloids of the plant kratom. The invention is underpinned by novel antibodies which specifically bind to mitragynine alkaloids found in the kratom plant and their metabolites.

Sol-gels and their use in water quality assays

First and second reactants that give a signal when mixed in the presence of an analyte in a liquid sample, are separately contained in sol-gels that release the reactants in the presence of the liquid. For example, when the first and second reactants respectively comprise an oxidant and a reductant, and the reaction provides a detectable signal, the system can be used to detect the presence of contaminants in a water sample. The sol-gel may be obtained by reaction of water with, per part by volume thereof, at least 2 parts of a metal alkoxide, and drying the resultant gel.

Mehranalyte immunoassay

Imaging method

A method for imaging molecules contained in an array of discrete reaction sites on the surface of a solid support comprises: (i) imaging the array and detecting a first molecule located on the solid support at a known position with respect to the array; (ii) by reference to the first molecule, aligning inspection windows in registration with the discrete reaction sites; and (iii) determining the amount of detectable signal in each window. The method is used to locate the reaction sites accurately on the array, and to correct for any misalignments.